oxygen hydride - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	oxygen hydride	go back to main search page
Accession:	CHEBI:33693	browse the term
Synonyms:	related_synonym:	hydrides of oxygen; oxygen hydrides

show annotations for term's descendants Sort by:
Rat (809) Mouse (823) Human (881) Chinchilla (0) Bonobo (0) Dog (2) Squirrel (0) Pig (5) Green Monkey (0) Naked Mole-rat (0) All
Genes (881)

Augmentin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 11

decreases expression

Amoxicillin-Potassium Clavulanate Combination results in decreased expression of ABCB11 mRNA

NCBI chr 2:168,915,390...169,031,324
Ensembl chr 2:168,915,498...169,031,324

G

aldo-keto reductase family 1 member B10

increases expression

Amoxicillin-Potassium Clavulanate Combination results in increased expression of AKR1B10 mRNA

NCBI chr 7:134,527,567...134,541,412
Ensembl chr 7:134,527,567...134,541,412

G

caspase 3

increases activity

Amoxicillin-Potassium Clavulanate Combination results in increased activity of CASP3 protein

NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062

G

caspase 9

increases activity

Amoxicillin-Potassium Clavulanate Combination results in increased activity of CASP9 protein

NCBI chr 1:15,491,401...15,524,912
Ensembl chr 1:15,490,832...15,526,534

G

C-X-C motif chemokine ligand 8

increases expression

Amoxicillin-Potassium Clavulanate Combination results in increased expression of CXCL8 protein

NCBI chr 4:73,740,569...73,743,716
Ensembl chr 4:73,740,519...73,743,716

G

cytochrome c, somatic

increases secretion

Amoxicillin-Potassium Clavulanate Combination results in increased secretion of CYCS protein

NCBI chr 7:25,118,656...25,125,260
Ensembl chr 7:25,118,656...25,125,260

G

cytochrome P450 family 27 subfamily A member 1

decreases expression

Amoxicillin-Potassium Clavulanate Combination results in decreased expression of CYP27A1 mRNA

NCBI chr 2:218,782,147...218,815,293
Ensembl chr 2:218,781,749...218,815,293

G

cytochrome P450 family 7 subfamily A member 1

decreases expression

Amoxicillin-Potassium Clavulanate Combination results in decreased expression of CYP7A1 mRNA

NCBI chr 8:58,490,178...58,500,163
Ensembl chr 8:58,490,178...58,500,163

G

cytochrome P450 family 8 subfamily B member 1

decreases expression

Amoxicillin-Potassium Clavulanate Combination results in decreased expression of CYP8B1 mRNA

NCBI chr 3:42,872,192...42,875,879
Ensembl chr 3:42,856,005...42,875,898

G

fibroblast growth factor 19

increases expression

Amoxicillin-Potassium Clavulanate Combination results in increased expression of FGF19 mRNA

NCBI chr11:69,698,238...69,704,022
Ensembl chr11:69,698,238...69,704,022

G

glucose-6-phosphate dehydrogenase

increases expression

Amoxicillin-Potassium Clavulanate Combination results in increased expression of G6PD mRNA

NCBI chr X:154,531,390...154,547,569
Ensembl chr X:154,517,825...154,547,572

G

glutamate-cysteine ligase catalytic subunit

increases expression

Amoxicillin-Potassium Clavulanate Combination results in increased expression of GCLC mRNA

NCBI chr 6:53,497,341...53,545,101
Ensembl chr 6:53,497,341...53,616,970

G

glutamate-cysteine ligase modifier subunit

increases expression

Amoxicillin-Potassium Clavulanate Combination results in increased expression of GCLM mRNA

NCBI chr 1:93,885,199...93,909,430
Ensembl chr 1:93,885,199...93,909,456

G

gamma-glutamyltransferase 1

increases expression

Amoxicillin-Potassium Clavulanate Combination results in increased expression of GGT1 protein

NCBI chr22:24,583,750...24,628,996
Ensembl chr22:24,594,811...24,629,005

G

glutamic-oxaloacetic transaminase 1

increases activity

Amoxicillin-Potassium Clavulanate Combination results in increased activity of GOT1 protein

NCBI chr10:99,396,870...99,430,624
Ensembl chr10:99,396,870...99,430,624

G

glutamic--pyruvic transaminase

increases activity

Amoxicillin-Potassium Clavulanate Combination results in increased activity of GPT protein

NCBI chr 8:144,503,068...144,507,172
Ensembl chr 8:144,502,973...144,507,174

G

glutathione peroxidase 2

increases expression

Amoxicillin-Potassium Clavulanate Combination results in increased expression of GPX2 mRNA

NCBI chr14:64,939,158...64,942,745
Ensembl chr14:64,939,152...64,942,746

G

glutathione-disulfide reductase

increases expression

Amoxicillin-Potassium Clavulanate Combination results in increased expression of GSR mRNA

NCBI chr 8:30,678,066...30,727,846
Ensembl chr 8:30,678,066...30,727,846

G

malic enzyme 1

increases expression

Amoxicillin-Potassium Clavulanate Combination results in increased expression of ME1 mRNA

NCBI chr 6:83,210,402...83,431,051
Ensembl chr 6:83,210,402...83,431,051

G

nuclear receptor subfamily 0 group B member 2

increases expression

Amoxicillin-Potassium Clavulanate Combination results in increased expression of NR0B2 mRNA

NCBI chr 1:26,911,489...26,913,975
Ensembl chr 1:26,911,489...26,913,975

G

solute carrier family 10 member 1

decreases expression

Amoxicillin-Potassium Clavulanate Combination results in decreased expression of SLC10A1 mRNA

NCBI chr14:69,775,416...69,797,241
Ensembl chr14:69,775,416...69,797,241

G

solute carrier family 51 member A

decreases expression

Amoxicillin-Potassium Clavulanate Combination results in decreased expression of SLC51A mRNA

NCBI chr 3:196,216,534...196,233,427
Ensembl chr 3:196,211,487...196,243,178

G

solute carrier family 7 member 11

increases expression

Amoxicillin-Potassium Clavulanate Combination results in increased expression of SLC7A11 mRNA

NCBI chr 4:138,164,097...138,312,671
Ensembl chr 4:138,164,097...138,242,349

G

transketolase

increases expression

Amoxicillin-Potassium Clavulanate Combination results in increased expression of TKT mRNA

NCBI chr 3:53,224,712...53,256,022
Ensembl chr 3:53,224,712...53,256,052

G

thioredoxin reductase 1

increases expression

Amoxicillin-Potassium Clavulanate Combination results in increased expression of TXNRD1 mRNA

NCBI chr12:104,215,779...104,350,307
Ensembl chr12:104,215,779...104,350,307

carbidopa

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

BCL2 associated X, apoptosis regulator

multiple interactions

[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased expression of BAX protein]; Carbidopa inhibits the reaction [Cisplatin results in increased expression of BAX protein]
Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased expression of BAX protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in increased expression of BAX protein]]; sarpogrelate promotes the reaction [Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased expression of BAX protein]]

PMID:34560070 PMID:35202708

NCBI chr19:48,954,875...48,961,798
Ensembl chr19:48,954,815...48,961,798

G

BCL2 apoptosis regulator

multiple interactions

[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein]; Carbidopa inhibits the reaction [Carbon Tetrachloride results in decreased expression of BCL2 protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in decreased expression of BCL2 protein]]; sarpogrelate promotes the reaction [Carbidopa inhibits the reaction [Carbon Tetrachloride results in decreased expression of BCL2 protein]]
[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein]; Carbidopa inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein]

PMID:34560070 PMID:35202708

NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128

G

caspase 3

multiple interactions

[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased cleavage of CASP3 protein]; Carbidopa inhibits the reaction [Cisplatin results in increased cleavage of CASP3 protein]
[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased cleavage of CASP3 protein]; Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased cleavage of CASP3 protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in increased cleavage of CASP3 protein]]; sarpogrelate promotes the reaction [Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased cleavage of CASP3 protein]]

PMID:34560070 PMID:35202708

NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062

G

caspase 9

multiple interactions

[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased cleavage of CASP9 protein]; Carbidopa inhibits the reaction [Cisplatin results in increased cleavage of CASP9 protein]
[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased cleavage of CASP9 protein]; Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased cleavage of CASP9 protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in increased cleavage of CASP9 protein]]; sarpogrelate promotes the reaction [Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased cleavage of CASP9 protein]]

PMID:34560070 PMID:35202708

NCBI chr 1:15,491,401...15,524,912
Ensembl chr 1:15,490,832...15,526,534

G

catechol-O-methyltransferase

increases methylation

COMT protein results in increased methylation of Carbidopa

NCBI chr22:19,941,772...19,969,975
Ensembl chr22:19,941,371...19,969,975

G

dopa decarboxylase

multiple interactions

[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Carbon Tetrachloride results in increased expression of DDC mRNA]
Carbidopa binds to and results in decreased activity of DDC protein

PMID:35151785 PMID:35202708

NCBI chr 7:50,458,442...50,565,405
Ensembl chr 7:50,458,436...50,565,405

G

dynamin 1 like

multiple interactions

Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased expression of DNM1L protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in increased expression of DNM1L protein]]; sarpogrelate promotes the reaction [Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased expression of DNM1L protein]]

NCBI chr12:32,679,301...32,745,650
Ensembl chr12:32,679,200...32,745,650

G

fission, mitochondrial 1

multiple interactions

Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased expression of FIS1 protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in increased expression of FIS1 protein]]; sarpogrelate promotes the reaction [Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased expression of FIS1 protein]]

NCBI chr 7:101,239,472...101,245,081
Ensembl chr 7:101,239,458...101,252,316

G

glutamic--pyruvic transaminase

multiple interactions

Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased activity of GPT protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in increased activity of GPT protein]]; sarpogrelate promotes the reaction [Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased activity of GPT protein]]

NCBI chr 8:144,503,068...144,507,172
Ensembl chr 8:144,502,973...144,507,174

G

interleukin 1 beta

multiple interactions

[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased expression of IL1B protein]
[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased secretion of IL1B protein]; Carbidopa inhibits the reaction [Cisplatin results in increased secretion of IL1B protein]

NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816

G

monoamine oxidase A

multiple interactions

[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Carbon Tetrachloride results in increased expression of MAOA mRNA]; [sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased expression of MAOA protein]; Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased expression of MAOA mRNA]; Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased expression of MAOA protein]; Carbidopa inhibits the reaction [Cisplatin results in increased expression of MAOA protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in increased expression of MAOA protein]]; sarpogrelate promotes the reaction [Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased expression of MAOA protein]]

PMID:34560070 PMID:35202708

NCBI chr X:43,655,006...43,746,817
Ensembl chr X:43,654,907...43,746,817

G

mitofusin 1

multiple interactions

[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Carbon Tetrachloride results in decreased expression of MFN1 protein]; Carbidopa inhibits the reaction [Carbon Tetrachloride results in decreased expression of MFN1 protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in decreased expression of MFN1 protein]]

NCBI chr 3:179,347,709...179,394,936
Ensembl chr 3:179,347,709...179,394,936

G

mitochondrially encoded ATP synthase membrane subunit 6

multiple interactions

Carbidopa inhibits the reaction [Carbon Tetrachloride results in decreased expression of ATP6 protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in decreased expression of ATP6 protein]]; sarpogrelate promotes the reaction [Carbidopa inhibits the reaction [Carbon Tetrachloride results in decreased expression of ATP6 protein]]

NCBI chr MT:8,527...9,207
Ensembl chr MT:8,527...9,207

G

mitochondrially encoded cytochrome b

multiple interactions

Carbidopa inhibits the reaction [Carbon Tetrachloride results in decreased expression of CYTB protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in decreased expression of CYTB protein]]; sarpogrelate promotes the reaction [Carbidopa inhibits the reaction [Carbon Tetrachloride results in decreased expression of CYTB protein]]

NCBI chr MT:14,747...15,887
Ensembl chr MT:14,747...15,887

G

mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 1

multiple interactions

[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Carbon Tetrachloride results in decreased expression of ND1 protein]; Carbidopa inhibits the reaction [Carbon Tetrachloride results in decreased expression of ND1 protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in decreased expression of ND1 protein]]

NCBI chr MT:3,307...4,262
Ensembl chr MT:3,307...4,262

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased phosphorylation of RELA protein]; Carbidopa inhibits the reaction [Cisplatin results in increased phosphorylation of RELA protein]

NCBI chr11:65,653,601...65,663,857
Ensembl chr11:65,653,599...65,663,090

G

synuclein alpha

multiple interactions

[Levodopa co-treated with Carbidopa] inhibits the reaction [Reserpine results in increased expression of SNCA protein]

NCBI chr 4:89,724,099...89,838,304
Ensembl chr 4:89,700,345...89,838,315

G

signal transducer and activator of transcription 3

multiple interactions

[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased phosphorylation of STAT3 protein]; Carbidopa inhibits the reaction [Cisplatin results in increased phosphorylation of STAT3 protein]

NCBI chr17:42,313,324...42,388,442
Ensembl chr17:42,313,324...42,388,568

G

tumor necrosis factor

multiple interactions

[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased secretion of TNF protein]; Carbidopa inhibits the reaction [Cisplatin results in increased secretion of TNF protein]
[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased expression of TNF protein]

NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336

G

tryptophan hydroxylase 1

multiple interactions

[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Carbon Tetrachloride results in increased expression of TPH1 mRNA]; [sarpogrelate co-treated with Carbidopa] inhibits the reaction [Carbon Tetrachloride results in increased expression of TPH1 protein]

NCBI chr11:18,017,555...18,046,269
Ensembl chr11:18,017,555...18,046,269

ceftazidime pentahydrate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily C member 4 (PEL blood group)

increases transport

ABCC4 protein results in increased transport of Ceftazidime

NCBI chr13:95,019,835...95,301,451
Ensembl chr13:95,019,835...95,301,475

G

dihydrofolate reductase

decreases activity

Ceftazidime results in decreased activity of DHFR protein

NCBI chr 5:80,626,226...80,654,983
Ensembl chr 5:80,626,226...80,654,983

G

heat shock transcription factor 1

decreases activity

Ceftazidime results in decreased activity of HSF1 protein

NCBI chr 8:144,291,604...144,314,720
Ensembl chr 8:144,291,591...144,314,720

G

interleukin 10

multiple interactions

Ceftazidime inhibits the reaction [Lipopolysaccharides results in increased secretion of IL10 protein]

NCBI chr 1:206,767,602...206,772,494
Ensembl chr 1:206,767,602...206,774,541

cilazapril monohydrate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

angiotensin I converting enzyme

affects response to substance

ACE gene polymorphism affects the susceptibility to Cilazapril

NCBI chr17:63,477,061...63,498,373
Ensembl chr17:63,477,061...63,498,380

G

adiponectin, C1Q and collagen domain containing

increases expression

Cilazapril results in increased expression of ADIPOQ protein

NCBI chr 3:186,842,710...186,858,463
Ensembl chr 3:186,842,704...186,858,463

G

angiotensin II receptor type 1

multiple interactions

[Cilazapril co-treated with Losartan] promotes the reaction [Doxorubicin results in increased expression of AGTR1 mRNA]; Cilazapril promotes the reaction [Doxorubicin results in increased expression of AGTR1 mRNA]

NCBI chr 3:148,697,903...148,743,003
Ensembl chr 3:148,697,784...148,743,008

G

angiotensin II receptor type 2

multiple interactions

[Losartan co-treated with Cilazapril] inhibits the reaction [Doxorubicin results in decreased expression of AGTR2 mRNA]; Cilazapril inhibits the reaction [Doxorubicin results in decreased expression of AGTR2 mRNA]

NCBI chr X:116,170,744...116,174,974
Ensembl chr X:116,170,744...116,174,974

G

fibroblast growth factor 2

decreases expression

Cilazapril results in decreased expression of FGF2 mRNA; Cilazapril results in decreased expression of FGF2 protein

NCBI chr 4:122,826,682...122,898,236
Ensembl chr 4:122,826,682...122,898,236

G

natriuretic peptide A

multiple interactions
affects secretion

[Cilazapril co-treated with Verapamil] affects the secretion of NPPA protein
Cilazapril affects the secretion of NPPA protein

NCBI chr 1:11,845,709...11,847,783
Ensembl chr 1:11,845,709...11,848,345

G

renin

increases activity

Cilazapril results in increased activity of REN protein

NCBI chr 1:204,154,819...204,166,337
Ensembl chr 1:204,154,819...204,190,324

G

solute carrier family 15 member 1

multiple interactions

Cilazapril inhibits the reaction [SLC15A1 protein results in increased uptake of glycylsarcosine]

NCBI chr13:98,683,801...98,752,672
Ensembl chr13:98,683,801...98,752,672

G

solute carrier family 15 member 2

multiple interactions

Cilazapril inhibits the reaction [SLC15A2 protein results in increased uptake of glycylsarcosine]

NCBI chr 3:121,894,401...121,944,188
Ensembl chr 3:121,894,401...121,944,188

G

transforming growth factor beta 1

multiple interactions

[Losartan co-treated with Cilazapril] inhibits the reaction [Doxorubicin results in increased expression of TGFB1 protein]; Cilazapril inhibits the reaction [Doxorubicin results in increased expression of TGFB1 protein]

NCBI chr19:41,330,323...41,353,922
Ensembl chr19:41,301,587...41,353,922

dideuterium oxide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

AKT serine/threonine kinase 1

decreases phosphorylation
multiple interactions

Deuterium Oxide results in decreased phosphorylation of AKT1 protein
Acetylcysteine inhibits the reaction [Deuterium Oxide results in decreased phosphorylation of AKT1 protein]

NCBI chr14:104,769,349...104,795,748
Ensembl chr14:104,769,349...104,795,759

G

AKT serine/threonine kinase 2

multiple interactions
decreases phosphorylation

Acetylcysteine inhibits the reaction [Deuterium Oxide results in decreased phosphorylation of AKT2 protein]

NCBI chr19:40,230,317...40,285,345
Ensembl chr19:40,230,317...40,285,536

G

AKT serine/threonine kinase 3

decreases phosphorylation
multiple interactions

Deuterium Oxide results in decreased phosphorylation of AKT3 protein
Acetylcysteine inhibits the reaction [Deuterium Oxide results in decreased phosphorylation of AKT3 protein]

NCBI chr 1:243,488,233...243,851,079
Ensembl chr 1:243,488,233...243,851,079

G

BCL2 associated X, apoptosis regulator

increases expression

Deuterium Oxide results in increased expression of BAX protein

NCBI chr19:48,954,875...48,961,798
Ensembl chr19:48,954,815...48,961,798

G

beclin 1

multiple interactions
increases expression

Acetylcysteine inhibits the reaction [Deuterium Oxide results in increased expression of BECN1 protein]

NCBI chr17:42,810,132...42,824,282
Ensembl chr17:42,810,134...42,833,350

G

caspase 3

increases cleavage

Deuterium Oxide results in increased cleavage of CASP3 protein

NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062

G

microtubule associated protein 1 light chain 3 beta

multiple interactions

Acetylcysteine inhibits the reaction [Deuterium Oxide results in increased expression of and results in increased lipidation of MAP1LC3B protein]; Deuterium Oxide results in increased expression of and results in increased lipidation of MAP1LC3B protein

NCBI chr16:87,392,336...87,404,774
Ensembl chr16:87,383,953...87,404,779

G

mechanistic target of rapamycin kinase

multiple interactions
decreases phosphorylation

Acetylcysteine inhibits the reaction [Deuterium Oxide results in decreased phosphorylation of MTOR protein]

NCBI chr 1:11,106,535...11,262,551
Ensembl chr 1:11,106,535...11,262,556

G

phosphoinositide-3-kinase regulatory subunit 1

decreases phosphorylation
multiple interactions

Deuterium Oxide results in decreased phosphorylation of PIK3R1 protein
Acetylcysteine inhibits the reaction [Deuterium Oxide results in decreased phosphorylation of PIK3R1 protein]

NCBI chr 5:68,215,756...68,301,821
Ensembl chr 5:68,215,740...68,301,821

dipotassium bis[mu-tartrato(4-)]diantimonate(2-) trihydrate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

alpha-2-macroglobulin

decreases expression

Antimony Potassium Tartrate results in decreased expression of A2M mRNA

NCBI chr12:9,067,708...9,116,229
Ensembl chr12:9,067,664...9,116,229

G

ATP binding cassette subfamily C member 1 (ABCC1 blood group)

affects response to substance
decreases response to substance
increases secretion
multiple interactions

ABCC1 protein affects the susceptibility to Antimony Potassium Tartrate
ABCC1 protein results in decreased susceptibility to Antimony Potassium Tartrate
ABCC1 protein results in increased secretion of Antimony Potassium Tartrate
[MYCN protein affects the expression of ABCC1 mRNA] which affects the susceptibility to Antimony Potassium Tartrate; Glutathione affects the reaction [ABCC1 protein results in increased secretion of Antimony Potassium Tartrate]; verlukast inhibits the reaction [ABCC1 protein results in decreased susceptibility to Antimony Potassium Tartrate]; verlukast inhibits the reaction [ABCC1 protein results in increased secretion of Antimony Potassium Tartrate]

PMID:10025956 PMID:10348353 PMID:11278867 PMID:12018890 PMID:12731862

NCBI chr16:15,949,143...16,143,053
Ensembl chr16:15,949,138...16,143,257

G

ATP binding cassette subfamily C member 2

increases expression
multiple interactions

Antimony Potassium Tartrate results in increased expression of ABCC2 mRNA; Antimony Potassium Tartrate results in increased expression of ABCC2 protein
[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of ABCC2 mRNA

PMID:11408547 PMID:32076005

NCBI chr10:99,782,640...99,852,594
Ensembl chr10:99,782,640...99,852,594

G

ATP binding cassette subfamily C member 3

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of ABCC3 mRNA

NCBI chr17:50,634,881...50,692,253
Ensembl chr17:50,634,777...50,692,253

G

acid phosphatase 2, lysosomal

decreases expression

Antimony Potassium Tartrate results in decreased expression of ACP2 mRNA

NCBI chr11:47,239,302...47,248,814
Ensembl chr11:47,239,302...47,248,906

G

acyl-CoA synthetase long chain family member 1

decreases expression

Antimony Potassium Tartrate results in decreased expression of ACSL1 mRNA

NCBI chr 4:184,755,595...184,826,594
Ensembl chr 4:184,755,595...184,826,818

G

adrenomedullin

increases expression

Antimony Potassium Tartrate results in increased expression of ADM mRNA

NCBI chr11:10,305,073...10,307,397
Ensembl chr11:10,305,073...10,307,397

G

aldo-keto reductase family 1 member B

decreases expression
increases expression

Antimony Potassium Tartrate results in decreased expression of AKR1B1 mRNA
Antimony Potassium Tartrate results in increased expression of AKR1B1 mRNA

PMID:17547211 PMID:28713220

NCBI chr 7:134,442,350...134,459,239
Ensembl chr 7:134,442,356...134,459,284

G

aldo-keto reductase family 1 member B10

increases expression
multiple interactions

Antimony Potassium Tartrate results in increased expression of AKR1B10 mRNA
[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of AKR1B10 mRNA

PMID:28713220 PMID:32076005

NCBI chr 7:134,527,567...134,541,412
Ensembl chr 7:134,527,567...134,541,412

G

aldo-keto reductase family 1 member C2

increases expression

Antimony Potassium Tartrate results in increased expression of AKR1C2 protein

NCBI chr10:4,987,775...5,018,000
Ensembl chr10:4,987,775...5,018,031

G

aldo-keto reductase family 1 member C3

increases expression
multiple interactions

Antimony Potassium Tartrate results in increased expression of AKR1C3 mRNA; Antimony Potassium Tartrate results in increased expression of AKR1C3 protein
[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of AKR1C3 mRNA

PMID:28713220 PMID:32076005

NCBI chr10:5,048,781...5,107,686
Ensembl chr10:5,035,354...5,107,686

G

aldehyde dehydrogenase 3 family member A2

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of ALDH3A2 mRNA

NCBI chr17:19,648,136...19,677,596
Ensembl chr17:19,648,136...19,685,760

G

aldehyde dehydrogenase 3 family member B2

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of ALDH3B2 mRNA

NCBI chr11:67,662,155...67,681,252
Ensembl chr11:67,662,155...67,681,224

G

aldehyde dehydrogenase 6 family member A1

decreases expression

Antimony Potassium Tartrate results in decreased expression of ALDH6A1 mRNA

NCBI chr14:74,056,847...74,084,453
Ensembl chr14:74,056,847...74,084,492

G

aldolase, fructose-bisphosphate A

increases expression

Antimony Potassium Tartrate results in increased expression of ALDOA mRNA

NCBI chr16:30,064,279...30,070,420
Ensembl chr16:30,064,164...30,070,457

G

aldolase, fructose-bisphosphate C

increases expression

Antimony Potassium Tartrate results in increased expression of ALDOC mRNA

NCBI chr17:28,573,120...28,576,895
Ensembl chr17:28,573,115...28,576,948

G

androgen receptor

increases phosphorylation

Antimony Potassium Tartrate results in increased phosphorylation of AR protein

NCBI chr X:67,544,021...67,730,619
Ensembl chr X:67,544,021...67,730,619

G

ATPase plasma membrane Ca2+ transporting 1

decreases expression

Antimony Potassium Tartrate results in decreased expression of ATP2B1 mRNA

NCBI chr12:89,588,049...89,709,366
Ensembl chr12:89,588,049...89,709,366

G

alpha-2-glycoprotein 1, zinc-binding

decreases expression

Antimony Potassium Tartrate results in decreased expression of AZGP1 mRNA

NCBI chr 7:99,966,730...99,976,031
Ensembl chr 7:99,966,720...99,976,042

G

BARX homeobox 2

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of BARX2 mRNA

NCBI chr11:129,375,233...129,452,279
Ensembl chr11:129,375,848...129,452,279

G

BCL2 associated X, apoptosis regulator

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of BAX protein

NCBI chr19:48,954,875...48,961,798
Ensembl chr19:48,954,815...48,961,798

G

BCL2 apoptosis regulator

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in decreased expression of BCL2 protein
666-15 compound promotes the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in decreased expression of BCL2 protein]; [Antimony Potassium Tartrate results in increased abundance of Antimony] which results in decreased expression of BCL2 protein

NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128

G

bone morphogenetic protein 6

multiple interactions

Antimony Potassium Tartrate inhibits the reaction [BMP6 protein results in increased expression of DUSP12 mRNA]; Antimony Potassium Tartrate inhibits the reaction [BMP6 protein results in increased expression of DUSP2 mRNA]

NCBI chr 6:7,726,099...7,881,728
Ensembl chr 6:7,726,099...7,881,728

G

basic transcription factor 3

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of BTF3 mRNA

NCBI chr 5:73,498,442...73,505,667
Ensembl chr 5:73,498,408...73,505,667

G

BTG anti-proliferation factor 2

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of BTG2 mRNA

NCBI chr 1:203,305,519...203,309,602
Ensembl chr 1:203,305,491...203,309,602

G

calmodulin like 5

decreases expression

Antimony Potassium Tartrate results in decreased expression of CALML5 mRNA

NCBI chr10:5,498,697...5,499,570
Ensembl chr10:5,498,697...5,499,570

G

calreticulin

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of CALR mRNA

NCBI chr19:12,938,609...12,944,489
Ensembl chr19:12,938,578...12,944,489

G

caspase 3

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased cleavage of CASP3 protein

NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062

G

carbonyl reductase 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of CBR1 mRNA

NCBI chr21:36,070,024...36,073,164
Ensembl chr21:36,069,941...36,073,166

G

cyclin B2

increases expression

Antimony Potassium Tartrate results in increased expression of CCNB2 mRNA

NCBI chr15:59,105,146...59,125,045
Ensembl chr15:59,105,126...59,125,045

G

cyclin D1

multiple interactions

666-15 compound inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of CCND1 protein]; [Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of CCND1 protein; SB 203580 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of CCND1 protein]; U 0126 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of CCND1 protein]

NCBI chr11:69,641,156...69,654,474
Ensembl chr11:69,641,156...69,654,474

G

cyclin dependent kinase inhibitor 1A

increases expression

Antimony Potassium Tartrate results in increased expression of CDKN1A mRNA

NCBI chr 6:36,676,463...36,687,332
Ensembl chr 6:36,676,460...36,687,337

G

cyclin dependent kinase inhibitor 2B

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of CDKN2B mRNA

NCBI chr 9:22,002,903...22,009,313
Ensembl chr 9:22,002,903...22,009,305

G

cyclin dependent kinase inhibitor 3

increases expression

Antimony Potassium Tartrate results in increased expression of CDKN3 mRNA

NCBI chr14:54,397,007...54,420,218
Ensembl chr14:54,396,849...54,420,218

G

CCAAT enhancer binding protein alpha

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of CEBPA mRNA

NCBI chr19:33,299,934...33,302,534
Ensembl chr19:33,299,934...33,302,534

G

complement factor B

decreases expression

Antimony Potassium Tartrate results in decreased expression of CFB mRNA

NCBI chr 6:31,946,095...31,952,084
Ensembl chr 6:31,945,650...31,952,086

G

CDC28 protein kinase regulatory subunit 2

increases expression

Antimony Potassium Tartrate results in increased expression of CKS2 mRNA

NCBI chr 9:89,311,195...89,316,703
Ensembl chr 9:89,311,195...89,316,703

G

calmegin

decreases expression

Antimony Potassium Tartrate results in decreased expression of CLGN mRNA

NCBI chr 4:140,388,453...140,427,648
Ensembl chr 4:140,388,453...140,427,661

G

CLPTM1 regulator of GABA type A receptor forward trafficking

decreases expression

Antimony Potassium Tartrate results in decreased expression of CLPTM1 mRNA

NCBI chr19:44,954,585...44,993,341
Ensembl chr19:44,954,585...44,993,341

G

CCHC-type zinc finger nucleic acid binding protein

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of CNBP mRNA

NCBI chr 3:129,167,827...129,183,896
Ensembl chr 3:129,167,827...129,183,922

G

cAMP responsive element binding protein 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased phosphorylation of CREB1 protein
[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased phosphorylation of CREB1 protein; pyrazolanthrone inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased phosphorylation of CREB1 protein]; SB 203580 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased phosphorylation of CREB1 protein]; U 0126 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased phosphorylation of CREB1 protein]

PMID:32920012 PMID:34571074

NCBI chr 2:207,529,962...207,605,988
Ensembl chr 2:207,529,737...207,605,988

G

cystatin SA

decreases expression

Antimony Potassium Tartrate results in decreased expression of CST2 mRNA

NCBI chr20:23,823,769...23,826,729
Ensembl chr20:23,823,769...23,826,729

G

cytochrome P450 family 1 subfamily B member 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of CYP1B1 mRNA

NCBI chr 2:38,067,509...38,076,151
Ensembl chr 2:38,066,973...38,109,902

G

DAZ associated protein 1

increases expression

Antimony Potassium Tartrate results in increased expression of DAZAP1 mRNA

NCBI chr19:1,407,586...1,435,684
Ensembl chr19:1,407,569...1,435,687

G

decapping mRNA 1A

increases expression

Antimony Potassium Tartrate results in increased expression of DCP1A mRNA

NCBI chr 3:53,283,429...53,347,543
Ensembl chr 3:53,283,429...53,347,586

G

dehydrogenase/reductase 9

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of DHRS9 mRNA

NCBI chr 2:169,067,077...169,096,167
Ensembl chr 2:169,064,789...169,096,167

G

DnaJ heat shock protein family (Hsp40) member B1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of DNAJB1 mRNA

NCBI chr19:14,514,769...14,560,391
Ensembl chr19:14,514,769...14,560,391

G

DnaJ heat shock protein family (Hsp40) member B4

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of DNAJB4 mRNA

NCBI chr 1:77,979,175...78,017,964
Ensembl chr 1:77,979,175...78,017,964

G

desmocollin 1

decreases expression
multiple interactions

Antimony Potassium Tartrate results in decreased expression of DSC1 mRNA
[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of DSC1 mRNA; U 0126 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of DSC1 mRNA]

PMID:28713220 PMID:32076005

NCBI chr18:31,129,236...31,162,856
Ensembl chr18:31,129,236...31,162,856

G

desmoglein 1

multiple interactions

2-tert-butyl-9-fluoro-3,6-dihydro-7H-benz(h)imidazo(4,5-f)isoquinoline-7-one promotes the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of DSG1 mRNA]; [Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of DSG1 mRNA; Hydrocortisone inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of DSG1 mRNA]; U 0126 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of DSG1 mRNA]

NCBI chr18:31,318,160...31,359,246
Ensembl chr18:31,318,160...31,359,246

G

dystonin

decreases expression

Antimony Potassium Tartrate results in decreased expression of DST protein

NCBI chr 6:56,457,996...56,954,830
Ensembl chr 6:56,457,987...56,954,830

G

dual oxidase 1

decreases expression
multiple interactions

Antimony Potassium Tartrate results in decreased expression of DUOX1 mRNA
Antimony Potassium Tartrate inhibits the reaction [IL4 protein results in increased expression of DUOX1 mRNA]

NCBI chr15:45,129,994...45,165,574
Ensembl chr15:45,129,933...45,165,576

G

dual oxidase maturation factor 1

decreases expression

Antimony Potassium Tartrate results in decreased expression of DUOXA1 mRNA

NCBI chr15:45,117,366...45,129,879
Ensembl chr15:45,117,366...45,129,938

G

dual specificity phosphatase 1

increases expression

Antimony Potassium Tartrate results in increased expression of DUSP1 mRNA

NCBI chr 5:172,768,096...172,771,195
Ensembl chr 5:172,768,096...172,771,195

G

dual specificity phosphatase 12

multiple interactions

Antimony Potassium Tartrate inhibits the reaction [BMP6 protein results in increased expression of DUSP12 mRNA]

NCBI chr 1:161,749,786...161,757,238
Ensembl chr 1:161,749,758...161,757,238

G

dual specificity phosphatase 2

multiple interactions

Antimony Potassium Tartrate inhibits the reaction [BMP6 protein results in increased expression of DUSP2 mRNA]

NCBI chr 2:96,143,169...96,145,440
Ensembl chr 2:96,143,169...96,145,440

G

early growth response 3

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of EGR3 mRNA

NCBI chr 8:22,687,659...22,693,480
Ensembl chr 8:22,687,659...22,693,480

G

ETS homologous factor

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of EHF mRNA

NCBI chr11:34,621,093...34,663,288
Ensembl chr11:34,621,093...34,663,288

G

E74 like ETS transcription factor 3

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of ELF3 mRNA

NCBI chr 1:202,010,587...202,017,183
Ensembl chr 1:202,007,945...202,017,183

G

EPH receptor A1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of EPHA1 protein

NCBI chr 7:143,391,129...143,408,856
Ensembl chr 7:143,390,289...143,408,856

G

EPH receptor A2

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of EPHA2 protein

NCBI chr 1:16,124,337...16,156,069
Ensembl chr 1:16,124,337...16,156,069

G

epoxide hydrolase 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of EPHX1 mRNA

NCBI chr 1:225,810,124...225,845,563
Ensembl chr 1:225,810,124...225,845,563

G

coagulation factor V

decreases expression

Antimony Potassium Tartrate results in decreased expression of F5 mRNA

NCBI chr 1:169,511,951...169,586,481
Ensembl chr 1:169,511,951...169,586,588

G

fatty acid binding protein 5

decreases expression

Antimony Potassium Tartrate results in decreased expression of FABP5 mRNA

NCBI chr 8:81,280,536...81,284,775
Ensembl chr 8:81,280,536...81,284,777

G

farnesyl-diphosphate farnesyltransferase 1

decreases expression

Antimony Potassium Tartrate results in decreased expression of FDFT1 mRNA

NCBI chr 8:11,795,582...11,839,298
Ensembl chr 8:11,795,573...11,839,395

G

farnesyl diphosphate synthase

decreases expression

Antimony Potassium Tartrate results in decreased expression of FDPS mRNA

NCBI chr 1:155,308,866...155,320,665
Ensembl chr 1:155,308,748...155,320,666

G

fibroblast growth factor receptor 3

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of FGFR3 mRNA

NCBI chr 4:1,793,293...1,808,867
Ensembl chr 4:1,793,293...1,808,872

G

filaggrin

decreases expression
multiple interactions

Antimony Potassium Tartrate results in decreased expression of FLG mRNA
2-tert-butyl-9-fluoro-3,6-dihydro-7H-benz(h)imidazo(4,5-f)isoquinoline-7-one promotes the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of FLG mRNA]; [Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of FLG mRNA; Hydrocortisone inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of FLG mRNA]; U 0126 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of FLG mRNA]

PMID:28713220 PMID:32076005

NCBI chr 1:152,302,165...152,325,239
Ensembl chr 1:152,302,165...152,325,239

G

Fos proto-oncogene, AP-1 transcription factor subunit

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of FOS mRNA

NCBI chr14:75,278,828...75,282,230
Ensembl chr14:75,278,826...75,282,230

G

FOS like 1, AP-1 transcription factor subunit

increases expression

Antimony Potassium Tartrate results in increased expression of FOSL1 mRNA

NCBI chr11:65,892,049...65,900,545
Ensembl chr11:65,892,049...65,900,573

G

forkhead box Q1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of FOXQ1 mRNA

NCBI chr 6:1,312,098...1,314,758
Ensembl chr 6:1,312,098...1,314,758

G

ferritin heavy chain 1

increases expression
multiple interactions

Antimony Potassium Tartrate results in increased expression of FTH1 mRNA; Antimony Potassium Tartrate results in increased expression of FTH1 protein
[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of FTH1 mRNA

PMID:28713220 PMID:32076005

NCBI chr11:61,964,285...61,967,634
Ensembl chr11:61,959,718...61,967,634

G

ferritin light chain

increases expression
multiple interactions

Antimony Potassium Tartrate results in increased expression of FTL mRNA
[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of FTL mRNA

PMID:28713220 PMID:32076005

NCBI chr19:48,965,309...48,966,879
Ensembl chr19:48,965,309...48,966,879

G

glucose-6-phosphate dehydrogenase

increases expression

Antimony Potassium Tartrate results in increased expression of G6PD mRNA; Antimony Potassium Tartrate results in increased expression of G6PD protein

NCBI chr X:154,531,390...154,547,569
Ensembl chr X:154,517,825...154,547,572

G

glyceraldehyde-3-phosphate dehydrogenase

increases expression

Antimony Potassium Tartrate results in increased expression of GAPDH mRNA

NCBI chr12:6,534,517...6,538,371
Ensembl chr12:6,534,512...6,538,374

G

glutamate-cysteine ligase catalytic subunit

increases expression
multiple interactions

Antimony Potassium Tartrate results in increased expression of GCLC mRNA; Antimony Potassium Tartrate results in increased expression of GCLC protein
[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of GCLC mRNA

PMID:28713220 PMID:32076005

NCBI chr 6:53,497,341...53,545,101
Ensembl chr 6:53,497,341...53,616,970

G

glutamate-cysteine ligase modifier subunit

increases expression
multiple interactions

Antimony Potassium Tartrate results in increased expression of GCLM mRNA
[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of GCLM mRNA

PMID:28713220 PMID:32076005

NCBI chr 1:93,885,199...93,909,430
Ensembl chr 1:93,885,199...93,909,456

G

glucosaminyl (N-acetyl) transferase 3, mucin type

increases expression

Antimony Potassium Tartrate results in increased expression of GCNT3 mRNA

NCBI chr15:59,611,783...59,622,723
Ensembl chr15:59,594,875...59,640,239

G

glial fibrillary acidic protein

multiple interactions

666-15 compound inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of GFAP protein]; [Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of GFAP mRNA; [Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of GFAP protein; SB 203580 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of GFAP mRNA]; SB 203580 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of GFAP protein]; U 0126 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of GFAP mRNA]

NCBI chr17:44,903,159...44,915,500
Ensembl chr17:44,903,159...44,916,937

G

gamma-glutamyltransferase 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of GGT1 mRNA

NCBI chr22:24,583,750...24,628,996
Ensembl chr22:24,594,811...24,629,005

G

growth hormone inducible transmembrane protein

decreases expression

Antimony Potassium Tartrate results in decreased expression of GHITM mRNA

NCBI chr10:84,139,509...84,153,568
Ensembl chr10:84,139,482...84,154,841

G

galactosidase alpha

increases expression

Antimony Potassium Tartrate results in increased expression of GLA mRNA

NCBI chr X:101,397,803...101,407,925
Ensembl chr X:101,393,273...101,408,012

G

glutaredoxin

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of GLRX mRNA

NCBI chr 5:95,813,849...95,822,726
Ensembl chr 5:95,751,319...95,822,726

G

glutathione peroxidase 2

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of GPX2 mRNA

NCBI chr14:64,939,158...64,942,745
Ensembl chr14:64,939,152...64,942,746

G

grainyhead like transcription factor 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of GRHL1 mRNA

NCBI chr 2:9,951,693...10,002,277
Ensembl chr 2:9,951,693...10,002,277

G

glutathione S-transferase omega 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of GSTO1 mRNA

NCBI chr10:104,254,173...104,267,455
Ensembl chr10:104,235,356...104,267,459

G

GTP binding protein 6 (putative)

increases expression

Antimony Potassium Tartrate results in increased expression of GTPBP6 mRNA

NCBI chr  X:304,759...318,796
NCBI chr  Y:304,759...318,796
Ensembl chr  Y:304,529...318,796
Ensembl chr  X:304,529...318,796

G

H4 clustered histone 3

increases expression

Antimony Potassium Tartrate results in increased expression of H4C3 mRNA

NCBI chr 6:26,103,933...26,104,337
Ensembl chr 6:26,103,933...26,104,337

G

helicase like transcription factor

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of HLTF mRNA

NCBI chr 3:149,030,063...149,086,533
Ensembl chr 3:149,030,127...149,086,554

G

high mobility group AT-hook 1

increases expression

Antimony Potassium Tartrate results in increased expression of HMGA1 mRNA

NCBI chr 6:34,236,873...34,246,231
Ensembl chr 6:34,236,873...34,246,231

G

heme oxygenase 1

increases expression
multiple interactions

Antimony Potassium Tartrate results in increased expression of HMOX1 mRNA; Antimony Potassium Tartrate results in increased expression of HMOX1 protein
[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of HMOX1 mRNA

PMID:17547211 PMID:28713220 PMID:32076005

NCBI chr22:35,381,096...35,394,207
Ensembl chr22:35,380,361...35,394,214

G

HOP homeobox

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of HOPX mRNA

NCBI chr 4:56,647,998...56,681,706
Ensembl chr 4:56,647,989...56,681,877

G

hydroxysteroid 17-beta dehydrogenase 2

decreases expression

Antimony Potassium Tartrate results in decreased expression of HSD17B2 mRNA

NCBI chr16:82,035,253...82,098,534
Ensembl chr16:82,035,004...82,098,534

G

hydroxysteroid 17-beta dehydrogenase 7

decreases expression

Antimony Potassium Tartrate results in decreased expression of HSD17B7 mRNA

NCBI chr 1:162,790,702...162,812,823
Ensembl chr 1:162,790,702...162,812,823

G

heat shock protein family A (Hsp70) member 1A

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of HSPA1A mRNA

NCBI chr 6:31,815,543...31,817,942
Ensembl chr 6:31,815,543...31,817,946

G

heat shock protein family A (Hsp70) member 8

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of HSPA8 mRNA

NCBI chr11:123,057,489...123,062,462
Ensembl chr11:123,057,489...123,063,230

G

heat shock protein family B (small) member 8

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of HSPB8 mRNA

NCBI chr12:119,178,931...119,194,746
Ensembl chr12:119,171,555...119,224,855

G

HIV-1 Tat interactive protein 2

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of HTATIP2 mRNA

NCBI chr11:20,363,714...20,383,782
Ensembl chr11:20,363,685...20,383,782

G

inhibitor of DNA binding 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of ID1 mRNA

NCBI chr20:31,605,289...31,606,510
Ensembl chr20:31,605,283...31,606,515

G

immediate early response 2

increases expression

Antimony Potassium Tartrate results in increased expression of IER2 mRNA

NCBI chr19:13,150,411...13,154,911
Ensembl chr19:13,150,411...13,154,911

G

interferon related developmental regulator 1

decreases expression

Antimony Potassium Tartrate results in decreased expression of IFRD1 mRNA

NCBI chr 7:112,423,174...112,477,203
Ensembl chr 7:112,422,887...112,481,017

G

IKAROS family zinc finger 2

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of IKZF2 mRNA

NCBI chr 2:212,999,698...213,152,456
Ensembl chr 2:212,999,691...213,152,427

G

interleukin 1 receptor antagonist

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of IL1RN mRNA

NCBI chr 2:113,099,360...113,134,014
Ensembl chr 2:113,099,315...113,134,016

G

interleukin 4

multiple interactions

Antimony Potassium Tartrate inhibits the reaction [IL4 protein results in increased expression of DUOX1 mRNA]

NCBI chr 5:132,673,989...132,682,678
Ensembl chr 5:132,673,986...132,682,678

G

inhibitor of growth family member 3

increases expression

Antimony Potassium Tartrate results in increased expression of ING3 mRNA

NCBI chr 7:120,950,777...120,977,216
Ensembl chr 7:120,950,763...120,977,216

G

integrin subunit beta 3 binding protein

increases expression

Antimony Potassium Tartrate results in increased expression of ITGB3BP mRNA

NCBI chr 1:63,440,770...63,529,187
Ensembl chr 1:63,440,770...63,593,721

G

inter-alpha-trypsin inhibitor heavy chain 3

decreases expression

Antimony Potassium Tartrate results in decreased expression of ITIH3 mRNA

NCBI chr 3:52,794,796...52,808,797
Ensembl chr 3:52,794,768...52,808,799

G

involucrin

decreases expression
multiple interactions

Antimony Potassium Tartrate results in decreased expression of IVL mRNA; Antimony Potassium Tartrate results in decreased expression of IVL protein
[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of IVL mRNA

PMID:28713220 PMID:32076005

NCBI chr 1:152,908,546...152,911,886
Ensembl chr 1:152,908,546...152,911,886

G

KLF transcription factor 5

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of KLF5 mRNA

NCBI chr13:73,054,976...73,077,538
Ensembl chr13:73,054,976...73,077,541

G

KLF transcription factor 6

increases expression

Antimony Potassium Tartrate results in increased expression of KLF6 mRNA

NCBI chr10:3,775,996...3,785,209
Ensembl chr10:3,775,996...3,785,281

G

kallikrein related peptidase 3

increases expression
multiple interactions

Antimony Potassium Tartrate results in increased expression of KLK3 mRNA; Antimony Potassium Tartrate results in increased expression of KLK3 protein
bicalutamide inhibits the reaction [Antimony Potassium Tartrate results in increased expression of KLK3 mRNA]

NCBI chr19:50,854,915...50,860,764
Ensembl chr19:50,854,915...50,860,764

G

keratin 1

multiple interactions

2-tert-butyl-9-fluoro-3,6-dihydro-7H-benz(h)imidazo(4,5-f)isoquinoline-7-one promotes the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of KRT1 mRNA]; [Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of KRT1 mRNA; Hydrocortisone inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of KRT1 mRNA]; U 0126 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of KRT1 mRNA]

NCBI chr12:52,674,736...52,680,407
Ensembl chr12:52,674,736...52,680,407

G

keratin 10

decreases expression
multiple interactions

Antimony Potassium Tartrate results in decreased expression of KRT10 mRNA; Antimony Potassium Tartrate results in decreased expression of KRT10 protein
2-tert-butyl-9-fluoro-3,6-dihydro-7H-benz(h)imidazo(4,5-f)isoquinoline-7-one promotes the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of KRT10 mRNA]; [Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of KRT10 mRNA; Hydrocortisone inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of KRT10 mRNA]; U 0126 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of KRT10 mRNA]

PMID:28713220 PMID:32076005

NCBI chr17:40,818,117...40,822,614
Ensembl chr17:40,818,117...40,822,614

G

keratinocyte differentiation associated protein

decreases expression

Antimony Potassium Tartrate results in decreased expression of KRTDAP mRNA

NCBI chr19:35,487,324...35,490,464
Ensembl chr19:35,487,324...35,495,558

G

lipase A, lysosomal acid type

decreases expression

Antimony Potassium Tartrate results in decreased expression of LIPA mRNA

NCBI chr10:89,213,572...89,251,775
Ensembl chr10:89,213,569...89,414,557

G

loricrin cornified envelope precursor protein

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of LORICRIN mRNA

NCBI chr 1:153,259,687...153,262,124
Ensembl chr 1:153,259,687...153,262,124

G

leucine rich repeats and immunoglobulin like domains 1

decreases expression

Antimony Potassium Tartrate results in decreased expression of LRIG1 mRNA

NCBI chr 3:66,378,797...66,501,121
Ensembl chr 3:66,378,797...66,501,263

G

lanosterol synthase

decreases expression

Antimony Potassium Tartrate results in decreased expression of LSS mRNA

NCBI chr21:46,188,446...46,228,774
Ensembl chr21:46,188,141...46,228,824

G

MAF bZIP transcription factor F

increases expression

Antimony Potassium Tartrate results in increased expression of MAFF mRNA

NCBI chr22:38,201,994...38,216,511
Ensembl chr22:38,200,767...38,216,507

G

mannosidase alpha class 1A member 2

decreases expression

Antimony Potassium Tartrate results in decreased expression of MAN1A2 mRNA

NCBI chr 1:117,367,449...117,528,872
Ensembl chr 1:117,367,449...117,528,872

G

monoamine oxidase A

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of MAOA mRNA

NCBI chr X:43,655,006...43,746,817
Ensembl chr X:43,654,907...43,746,817

G

mitogen-activated protein kinase kinase 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of MAP2K1 mRNA

NCBI chr15:66,386,912...66,491,544
Ensembl chr15:66,386,837...66,491,656

G

mitogen-activated protein kinase 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased phosphorylation of MAPK1 protein
[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased phosphorylation of MAPK1 protein

PMID:32076005 PMID:32920012 PMID:34571074

NCBI chr22:21,759,657...21,867,680
Ensembl chr22:21,759,657...21,867,680

G

mitogen-activated protein kinase 3

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased phosphorylation of MAPK3 protein
[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased phosphorylation of MAPK3 protein

PMID:32076005 PMID:32920012 PMID:34571074

NCBI chr16:30,114,105...30,123,220
Ensembl chr16:30,114,105...30,123,506

G

minichromosome maintenance complex component 2

increases expression

Antimony Potassium Tartrate results in increased expression of MCM2 mRNA

NCBI chr 3:127,598,411...127,622,436
Ensembl chr 3:127,598,223...127,622,436

G

malic enzyme 1

increases expression

Antimony Potassium Tartrate results in increased expression of ME1 mRNA

NCBI chr 6:83,210,402...83,431,051
Ensembl chr 6:83,210,402...83,431,051

G

alpha-1,6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase

decreases expression

Antimony Potassium Tartrate results in decreased expression of MGAT2 mRNA

NCBI chr14:49,620,799...49,623,481
Ensembl chr14:49,620,799...49,623,481

G

microsomal glutathione S-transferase 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of MGST1 mRNA

NCBI chr12:16,347,115...16,593,331
Ensembl chr12:16,347,142...16,609,259

G

metallothionein 1E

increases expression

Antimony Potassium Tartrate results in increased expression of MT1E mRNA

NCBI chr16:56,625,781...56,627,112
Ensembl chr16:56,625,475...56,627,112

G

metallothionein 1X

decreases expression
increases expression

Antimony Potassium Tartrate results in decreased expression of MT1X mRNA
Antimony Potassium Tartrate results in increased expression of MT1X mRNA

PMID:17547211 PMID:28713220

NCBI chr16:56,682,470...56,684,196
Ensembl chr16:56,682,470...56,684,196

G

metallothionein 2A

increases expression

Antimony Potassium Tartrate results in increased expression of MT2A mRNA

NCBI chr16:56,608,584...56,609,497
Ensembl chr16:56,608,584...56,609,497

G

MYCN proto-oncogene, bHLH transcription factor

multiple interactions
decreases response to substance

[MYCN protein affects the expression of ABCC1 mRNA] which affects the susceptibility to Antimony Potassium Tartrate
MYCN protein results in decreased susceptibility to Antimony Potassium Tartrate

NCBI chr 2:15,940,550...15,947,004
Ensembl chr 2:15,940,550...15,947,007

G

NDRG family member 2

decreases expression

Antimony Potassium Tartrate results in decreased expression of NDRG2 mRNA

NCBI chr14:21,016,763...21,070,872
Ensembl chr14:21,016,763...21,070,872

G

nuclear factor kappa B subunit 2

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of NFKB2 mRNA

NCBI chr10:102,394,110...102,402,529
Ensembl chr10:102,394,110...102,402,524

G

NFKB inhibitor alpha

decreases expression

Antimony Potassium Tartrate results in decreased expression of NFKBIA mRNA

NCBI chr14:35,401,513...35,404,749
Ensembl chr14:35,401,079...35,404,749

G

NK3 homeobox 1

increases expression
multiple interactions

Antimony Potassium Tartrate results in increased expression of NKX3-1 mRNA; Antimony Potassium Tartrate results in increased expression of NKX3-1 protein
bicalutamide inhibits the reaction [Antimony Potassium Tartrate results in increased expression of NKX3-1 mRNA]

NCBI chr 8:23,678,693...23,682,938
Ensembl chr 8:23,678,697...23,682,938

G

nitric oxide synthase 2

multiple interactions

666-15 compound inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of NOS2 protein]; [Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of NOS2 mRNA; [Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of NOS2 protein; SB 203580 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of NOS2 mRNA]; SB 203580 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of NOS2 protein]

NCBI chr17:27,756,766...27,800,529
Ensembl chr17:27,756,766...27,800,529

G

NAD(P)H quinone dehydrogenase 1

increases expression
multiple interactions

Antimony Potassium Tartrate results in increased expression of NQO1 mRNA; Antimony Potassium Tartrate results in increased expression of NQO1 protein
[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of NQO1 mRNA

PMID:28713220 PMID:32076005

NCBI chr16:69,709,401...69,726,560
Ensembl chr16:69,706,996...69,726,668

G

N-ribosyldihydronicotinamide:quinone dehydrogenase 2

increases expression

Antimony Potassium Tartrate results in increased expression of NQO2 mRNA

NCBI chr 6:2,999,894...3,019,755
Ensembl chr 6:2,987,987...3,019,755

G

nuclear receptor subfamily 0 group B member 2

decreases expression

Antimony Potassium Tartrate results in decreased expression of NR0B2 mRNA

NCBI chr 1:26,911,489...26,913,975
Ensembl chr 1:26,911,489...26,913,975

G

OS9 endoplasmic reticulum lectin

decreases expression

Antimony Potassium Tartrate results in decreased expression of OS9 mRNA

NCBI chr12:57,694,132...57,721,557
Ensembl chr12:57,693,841...57,728,342

G

oncostatin M

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] inhibits the reaction [OSM protein results in increased phosphorylation of STAT1 protein]

NCBI chr22:30,262,829...30,266,851
Ensembl chr22:30,262,829...30,266,851

G

PBX homeobox 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of PBX1 mRNA

NCBI chr 1:164,559,184...164,886,047
Ensembl chr 1:164,555,584...164,899,296

G

proliferating cell nuclear antigen

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of PCNA protein

NCBI chr20:5,114,953...5,126,622
Ensembl chr20:5,114,953...5,126,626

G

protein disulfide isomerase family A member 4

decreases expression

Antimony Potassium Tartrate results in decreased expression of PDIA4 mRNA

NCBI chr 7:149,003,051...149,028,505
Ensembl chr 7:149,003,062...149,028,662

G

progastricsin

decreases expression

Antimony Potassium Tartrate results in decreased expression of PGC mRNA

NCBI chr 6:41,736,711...41,747,397
Ensembl chr 6:41,736,711...41,754,109

G

phosphogluconate dehydrogenase

increases expression

Antimony Potassium Tartrate results in increased expression of PGD protein

NCBI chr 1:10,399,064...10,420,511
Ensembl chr 1:10,398,592...10,420,511

G

phosphoglucomutase 1

increases expression

Antimony Potassium Tartrate results in increased expression of PGM1 mRNA

NCBI chr 1:63,593,411...63,660,245
Ensembl chr 1:63,593,411...63,660,245

G

phosphoglucomutase 3

increases expression

Antimony Potassium Tartrate results in increased expression of PGM3 mRNA

NCBI chr 6:83,148,705...83,193,900
Ensembl chr 6:83,147,324...83,193,936

G

phosphoinositide-3-kinase regulatory subunit 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of PIK3R1 mRNA

NCBI chr 5:68,215,756...68,301,821
Ensembl chr 5:68,215,740...68,301,821

G

phosphoinositide-3-kinase regulatory subunit 2

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of PIK3R2 mRNA

NCBI chr19:18,153,163...18,170,532
Ensembl chr19:18,153,163...18,170,532

G

pirin

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of PIR mRNA

NCBI chr X:15,384,799...15,493,333
Ensembl chr X:15,384,799...15,493,564

G

paired like homeodomain 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of PITX1 mRNA

NCBI chr 5:135,027,734...135,034,789
Ensembl chr 5:135,027,734...135,034,813

G

PML nuclear body scaffold

affects localization
multiple interactions
increases degradation

Antimony Potassium Tartrate affects the localization of PML protein
Antimony Potassium Tartrate promotes the reaction [SUMO1 protein binds to PML protein]
Antimony Potassium Tartrate results in increased degradation of PML protein mutant form

NCBI chr15:73,994,716...74,047,827
Ensembl chr15:73,994,673...74,047,827

G

RNA polymerase II subunit J2

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of POLR2J2 mRNA

NCBI chr 7:102,666,046...102,671,663
Ensembl chr 7:102,665,368...102,671,663

G

peptidylprolyl isomerase H

increases expression

Antimony Potassium Tartrate results in increased expression of PPIH mRNA

NCBI chr 1:42,658,423...42,681,654
Ensembl chr 1:42,658,335...42,676,758

G

peroxiredoxin 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of PRDX1 mRNA

NCBI chr 1:45,511,051...45,522,890
Ensembl chr 1:45,510,914...45,542,732

G

phosphoserine phosphatase

decreases expression

Antimony Potassium Tartrate results in decreased expression of PSPH mRNA

NCBI chr 7:56,011,064...56,051,444
Ensembl chr 7:56,011,051...56,051,604

G

PTTG1 regulator of sister chromatid separation, securin

increases expression

Antimony Potassium Tartrate results in increased expression of PTTG1 mRNA

NCBI chr 5:160,421,855...160,428,744
Ensembl chr 5:160,421,855...160,428,739

G

retinoic acid receptor alpha

increases degradation

Antimony Potassium Tartrate results in increased degradation of RARA protein mutant form

NCBI chr17:40,309,180...40,357,643
Ensembl chr17:40,309,180...40,357,643

G

RNA binding protein, mRNA processing factor

increases expression

Antimony Potassium Tartrate results in increased expression of RBPMS mRNA

NCBI chr 8:30,384,541...30,572,256
Ensembl chr 8:30,384,511...30,572,256

G

replication factor C subunit 2

increases expression

Antimony Potassium Tartrate results in increased expression of RFC2 mRNA

NCBI chr 7:74,231,502...74,254,399
Ensembl chr 7:74,231,499...74,254,458

G

ribonuclease H2 subunit A

increases expression

Antimony Potassium Tartrate results in increased expression of RNASEH2A mRNA

NCBI chr19:12,806,584...12,813,640
Ensembl chr19:12,806,584...12,813,640

G

ribonuclease/angiogenin inhibitor 1

decreases expression

Antimony Potassium Tartrate results in decreased expression of RNH1 protein

NCBI chr11:494,515...507,242
Ensembl chr11:494,512...507,300

G

repetin

decreases expression

Antimony Potassium Tartrate results in decreased expression of RPTN mRNA

NCBI chr 1:152,153,595...152,159,228
Ensembl chr 1:152,153,595...152,159,228

G

ryanodine receptor 1

decreases expression

Antimony Potassium Tartrate results in decreased expression of RYR1 mRNA

NCBI chr19:38,433,691...38,587,564
Ensembl chr19:38,433,691...38,595,273

G

S100 calcium binding protein A12

decreases expression

Antimony Potassium Tartrate results in decreased expression of S100A12 mRNA

NCBI chr 1:153,373,711...153,375,621
Ensembl chr 1:153,373,711...153,375,621

G

S100 calcium binding protein A2

decreases expression

Antimony Potassium Tartrate results in decreased expression of S100A2 mRNA

NCBI chr 1:153,561,108...153,565,844
Ensembl chr 1:153,561,108...153,567,890

G

S100 calcium binding protein A7

decreases expression

Antimony Potassium Tartrate results in decreased expression of S100A7 mRNA

NCBI chr 1:153,457,744...153,460,651
Ensembl chr 1:153,457,744...153,460,651

G

S100 calcium binding protein A8

decreases expression

Antimony Potassium Tartrate results in decreased expression of S100A8 mRNA; Antimony Potassium Tartrate results in decreased expression of S100A8 protein

NCBI chr 1:153,390,032...153,422,583
Ensembl chr 1:153,390,032...153,391,073

G

S100 calcium binding protein A9

decreases expression

Antimony Potassium Tartrate results in decreased expression of S100A9 mRNA; Antimony Potassium Tartrate results in decreased expression of S100A9 protein

NCBI chr 1:153,357,854...153,361,023
Ensembl chr 1:153,357,854...153,361,023

G

stearoyl-CoA desaturase

decreases expression

Antimony Potassium Tartrate results in decreased expression of SCD mRNA

NCBI chr10:100,347,233...100,364,826
Ensembl chr10:100,347,233...100,364,826

G

selenophosphate synthetase 2

decreases expression

Antimony Potassium Tartrate results in decreased expression of SEPHS2 mRNA

NCBI chr16:30,443,631...30,445,874
Ensembl chr16:30,443,631...30,445,874

G

serpin family B member 1

decreases expression

Antimony Potassium Tartrate results in decreased expression of SERPINB1 mRNA

NCBI chr 6:2,832,332...2,841,863
Ensembl chr 6:2,832,332...2,841,959

G

serpin family C member 1

decreases expression

Antimony Potassium Tartrate results in decreased expression of SERPINC1 mRNA

NCBI chr 1:173,903,800...173,917,327
Ensembl chr 1:173,903,800...173,917,327

G

serpin family E member 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of SERPINE1 mRNA

NCBI chr 7:101,127,104...101,139,247
Ensembl chr 7:101,127,104...101,139,247

G

salt inducible kinase 1

increases expression

Antimony Potassium Tartrate results in increased expression of SIK1 mRNA

NCBI chr21:43,414,483...43,427,131
Ensembl chr21:43,414,483...43,427,131

G

solute carrier family 2 member 3

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of SLC2A3 mRNA

NCBI chr12:7,919,230...7,936,187
Ensembl chr12:7,919,230...8,019,007

G

small nuclear ribonucleoprotein polypeptide A

increases expression

Antimony Potassium Tartrate results in increased expression of SNRPA mRNA

NCBI chr19:40,751,203...40,765,389
Ensembl chr19:40,750,637...40,765,389

G

superoxide dismutase 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of SOD1 mRNA

NCBI chr21:31,659,693...31,668,931
Ensembl chr21:31,659,666...31,668,931

G

small proline rich protein 1A

decreases expression

Antimony Potassium Tartrate results in decreased expression of SPRR1A mRNA; Antimony Potassium Tartrate results in decreased expression of SPRR1A protein

NCBI chr 1:152,984,081...152,985,814
Ensembl chr 1:152,984,081...152,985,814

G

small proline rich protein 1B

decreases expression

Antimony Potassium Tartrate results in decreased expression of SPRR1B mRNA; Antimony Potassium Tartrate results in decreased expression of SPRR1B protein

NCBI chr 1:153,031,203...153,032,900
Ensembl chr 1:153,031,203...153,032,900

G

small proline rich protein 3

decreases expression

Antimony Potassium Tartrate results in decreased expression of SPRR3 mRNA; Antimony Potassium Tartrate results in decreased expression of SPRR3 protein

NCBI chr 1:153,001,749...153,003,856
Ensembl chr 1:153,001,747...153,003,856

G

squalene epoxidase

decreases expression

Antimony Potassium Tartrate results in decreased expression of SQLE mRNA

NCBI chr 8:124,998,505...125,022,283
Ensembl chr 8:124,998,497...125,022,283

G

sequestosome 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of SQSTM1 mRNA

NCBI chr 5:179,806,393...179,838,078
Ensembl chr 5:179,806,398...179,838,078

G

serine and arginine rich splicing factor 1

decreases expression

Antimony Potassium Tartrate results in decreased expression of SRSF1 mRNA

NCBI chr17:57,989,038...58,007,246
Ensembl chr17:58,000,919...58,007,346

G

serine and arginine rich splicing factor 5

decreases expression

Antimony Potassium Tartrate results in decreased expression of SRSF5 mRNA

NCBI chr14:69,767,142...69,772,005
Ensembl chr14:69,726,900...69,772,005

G

sulfiredoxin 1

increases expression

Antimony Potassium Tartrate results in increased expression of SRXN1 mRNA

NCBI chr20:646,615...653,200
Ensembl chr20:646,615...653,200

G

ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 4

decreases expression

Antimony Potassium Tartrate results in decreased expression of ST6GALNAC4 mRNA

NCBI chr 9:127,907,886...127,917,041
Ensembl chr 9:127,907,886...127,917,041

G

signal transducer and activator of transcription 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] inhibits the reaction [OSM protein results in increased phosphorylation of STAT1 protein]; [Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of STAT1 mRNA

NCBI chr 2:190,969,149...191,014,171
Ensembl chr 2:190,908,460...191,020,960

G

sulfotransferase family 1C member 3

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of SULT1C3 mRNA

NCBI chr 2:108,239,968...108,265,351
Ensembl chr 2:108,239,968...108,265,351

G

sulfotransferase family 1E member 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of SULT1E1 mRNA

NCBI chr 4:69,821,122...69,860,145
Ensembl chr 4:69,841,212...69,860,145

G

sulfotransferase family 2B member 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of SULT2B1 mRNA

NCBI chr19:48,552,172...48,599,427
Ensembl chr19:48,552,172...48,599,425

G

small ubiquitin like modifier 1

affects localization
multiple interactions

Antimony Potassium Tartrate affects the localization of SUMO1 protein
Antimony Potassium Tartrate promotes the reaction [SUMO1 protein binds to PML protein]

NCBI chr 2:202,206,171...202,238,597
Ensembl chr 2:202,206,182...202,238,599

G

TAR DNA binding protein

decreases expression

Antimony Potassium Tartrate results in decreased expression of TARDBP mRNA

NCBI chr 1:11,012,654...11,030,528
Ensembl chr 1:11,012,344...11,030,528

G

transglutaminase 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of TGM1 mRNA

NCBI chr14:24,249,114...24,263,177
Ensembl chr14:24,249,114...24,264,432

G

TNF alpha induced protein 3

increases expression

Antimony Potassium Tartrate results in increased expression of TNFAIP3 mRNA

NCBI chr 6:137,866,349...137,883,312
Ensembl chr 6:137,867,214...137,883,314

G

TNF superfamily member 10

decreases expression

Antimony Potassium Tartrate results in decreased expression of TNFSF10 mRNA

NCBI chr 3:172,505,508...172,523,430
Ensembl chr 3:172,505,508...172,523,475

G

transducer of ERBB2, 1

decreases expression

Antimony Potassium Tartrate results in decreased expression of TOB1 mRNA

NCBI chr17:50,862,223...50,867,978
Ensembl chr17:50,862,223...50,867,978

G

tumor protein p63

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of TP63 mRNA

NCBI chr 3:189,596,746...189,897,276
Ensembl chr 3:189,631,389...189,897,276

G

triosephosphate isomerase 1

increases expression

Antimony Potassium Tartrate results in increased expression of TPI1 mRNA

NCBI chr12:6,867,420...6,870,948
Ensembl chr12:6,867,119...6,870,948

G

TSC22 domain family member 3

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of TSC22D3 mRNA

NCBI chr X:107,713,221...107,775,988
Ensembl chr X:107,713,221...107,777,342

G

tetraspanin 7

decreases expression

Antimony Potassium Tartrate results in decreased expression of TSPAN7 mRNA

NCBI chr X:38,561,542...38,688,918
Ensembl chr X:38,561,542...38,688,920

G

tuftelin 1

increases expression

Antimony Potassium Tartrate results in increased expression of TUFT1 mRNA

NCBI chr 1:151,540,309...151,583,583
Ensembl chr 1:151,540,305...151,583,583

G

thioredoxin

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of TXN mRNA

NCBI chr 9:110,243,810...110,256,507
Ensembl chr 9:110,243,810...110,256,507

G

thioredoxin reductase 1

increases expression
multiple interactions

Antimony Potassium Tartrate results in increased expression of TXNRD1 mRNA
[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of TXNRD1 mRNA

PMID:17547211 PMID:28713220 PMID:32076005

NCBI chr12:104,215,779...104,350,307
Ensembl chr12:104,215,779...104,350,307

G

thymidylate synthetase

increases expression

Antimony Potassium Tartrate results in increased expression of TYMS mRNA

NCBI chr18:657,653...673,578
Ensembl chr18:657,653...673,578

G

ubiquitin conjugating enzyme E2 C

increases expression

Antimony Potassium Tartrate results in increased expression of UBE2C mRNA

NCBI chr20:45,812,644...45,816,952
Ensembl chr20:45,812,576...45,816,957

G

UDP glucuronosyltransferase family 1 member A6

increases expression
multiple interactions

Antimony Potassium Tartrate results in increased expression of UGT1A6 mRNA
[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of UGT1A6 mRNA

PMID:28713220 PMID:32076005

NCBI chr 2:233,691,702...233,773,300
Ensembl chr 2:233,691,607...233,773,300

G

ZW10 interacting kinetochore protein

increases expression

Antimony Potassium Tartrate results in increased expression of ZWINT mRNA

NCBI chr10:56,357,227...56,361,273
Ensembl chr10:56,357,227...56,361,273

diprotium oxide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

agouti related neuropeptide

multiple interactions

[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of AGRP mRNA; AM 251 promotes the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of AGRP mRNA]

NCBI chr16:67,482,571...67,483,547
Ensembl chr16:67,482,571...67,483,547

G

AKT serine/threonine kinase 1

multiple interactions

[[Particulate Matter co-treated with Water] results in increased abundance of Metals] which results in increased expression of AKT1 mRNA

NCBI chr14:104,769,349...104,795,748
Ensembl chr14:104,769,349...104,795,759

G

aquaporin 1 (Colton blood group)

increases transport
multiple interactions

AQP1 protein results in increased transport of Water
Mercuric Chloride inhibits the reaction [AQP1 protein results in increased transport of Water]; Mercury inhibits the reaction [AQP1 protein results in increased transport of Water]

PMID:7528928 PMID:8457558 PMID:10559675 PMID:11035042 PMID:11078688 More...

NCBI chr 7:30,911,853...30,925,516
Ensembl chr 7:30,911,853...30,925,517

G

aquaporin 11

multiple interactions
increases transport

Mercaptoethanol inhibits the reaction [Mercuric Chloride inhibits the reaction [AQP11 protein results in increased transport of Water]]; Mercuric Chloride inhibits the reaction [AQP11 protein results in increased transport of Water]

NCBI chr11:77,589,953...77,610,356
Ensembl chr11:77,589,391...77,610,356

G

aquaporin 2

increases expression

Water deficiency results in increased expression of AQP2 mRNA

NCBI chr12:49,950,737...49,958,878
Ensembl chr12:49,950,737...49,958,878

G

aquaporin 3 (Gill blood group)

multiple interactions
increases expression
increases transport

Dexamethasone promotes the reaction [AQP3 protein results in increased transport of Water]; Mercaptoethanol inhibits the reaction [Mercuric Chloride inhibits the reaction [AQP3 protein results in increased transport of Water]]; Mercuric Chloride inhibits the reaction [AQP3 protein results in increased transport of Water]; Mercuric Chloride inhibits the reaction [Dexamethasone promotes the reaction [AQP3 protein results in increased transport of Water]]
Water deficiency results in increased expression of AQP3 mRNA; Water deficiency results in increased expression of AQP3 protein
Copper Sulfate inhibits the reaction [AQP3 protein results in increased transport of Water]; Mercuric Chloride inhibits the reaction [AQP3 protein results in increased transport of Water]

PMID:9124401 PMID:9374739 PMID:15462210 PMID:22687538

NCBI chr 9:33,441,160...33,447,593
Ensembl chr 9:33,441,156...33,447,596

G

aquaporin 4

increases transport
increases response to substance
increases expression
affects transport

AQP4 protein results in increased transport of Water
AQP4 protein results in increased susceptibility to Water
Water deficiency results in increased expression of AQP4 mRNA
AQP4 protein affects the transport of Water

PMID:7528931 PMID:15462210 PMID:20815926 PMID:21251984

NCBI chr18:26,852,038...26,865,803
Ensembl chr18:26,852,043...26,865,771

G

aquaporin 7

affects transport
increases transport

AQP7 protein affects the transport of Water
AQP7 protein results in increased transport of Water

PMID:9252401 PMID:18059526

NCBI chr 9:33,383,191...33,402,568
Ensembl chr 9:33,383,179...33,402,682

G

aquaporin 8

multiple interactions
increases transport
affects transport

Copper affects the reaction [AQP8 protein affects the transport of Water]; Mercury affects the reaction [AQP8 protein affects the transport of Water]
AQP8 protein results in increased transport of Water
Mercuric Chloride inhibits the reaction [AQP8 protein results in increased transport of Water]

PMID:18059526 PMID:19840149

NCBI chr16:25,216,947...25,228,932
Ensembl chr16:25,215,731...25,228,932

G

aquaporin 9

multiple interactions
increases transport
affects transport

CFTR protein promotes the reaction [AQP9 protein affects the transport of Water]; lonidamine inhibits the reaction [CFTR protein promotes the reaction [AQP9 protein affects the transport of Water]]; Mercuric Chloride inhibits the reaction [AQP9 protein results in increased transport of Water]; Mercury inhibits the reaction [AQP9 protein results in increased transport of Water]; Phloretin inhibits the reaction [AQP9 protein results in increased transport of Water]; Phloretin inhibits the reaction [CFTR protein promotes the reaction [AQP9 protein affects the transport of Water]]

PMID:9514918 PMID:9733774 PMID:10205677 PMID:12606488 PMID:21259319 More...

NCBI chr15:58,138,169...58,185,911
Ensembl chr15:58,138,169...58,185,911

G

arginine vasopressin

multiple interactions

[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of AVP mRNA; [Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased secretion of AVP protein; AM 251 promotes the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of AVP mRNA]; arachidonyl-2-chloroethylamide inhibits the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of AVP mRNA]

NCBI chr20:3,082,556...3,084,724
Ensembl chr20:3,082,556...3,084,724

G

BCL2 apoptosis regulator

multiple interactions

[[Particulate Matter co-treated with Water] results in increased abundance of Metals] which results in increased expression of BCL2 mRNA

NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128

G

beclin 1

multiple interactions

[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of BECN1 protein; Berberine promotes the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of BECN1 protein]

NCBI chr17:42,810,132...42,824,282
Ensembl chr17:42,810,134...42,833,350

G

BCL2 interacting protein 3

multiple interactions

[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of BNIP3 protein; Berberine promotes the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of BNIP3 protein]

NCBI chr10:131,967,684...131,981,923
Ensembl chr10:131,967,684...131,981,967

G

CART prepropeptide

multiple interactions

[AM 251 co-treated with Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of CARTPT mRNA; [arachidonyl-2-chloroethylamide co-treated with Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of CARTPT mRNA

NCBI chr 5:71,719,275...71,721,045
Ensembl chr 5:71,719,275...71,721,048

G

caspase 1

multiple interactions

[[Particulate Matter co-treated with Water] results in increased abundance of Metals] which affects the expression of CASP1 mRNA; [Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of and results in increased cleavage of CASP1 protein; [Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of CASP1 mRNA; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of and results in increased cleavage of CASP1 protein]; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of CASP1 mRNA]

PMID:29335169 PMID:38705399

NCBI chr11:105,025,443...105,036,686
Ensembl chr11:105,025,397...105,035,250

G

caspase 3

multiple interactions

[Water deficiency co-treated with Diclofenac] results in increased expression of CASP3 protein; Gum Arabic inhibits the reaction [[Water deficiency co-treated with Diclofenac] results in increased expression of CASP3 protein]

NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062

G

catalase

multiple interactions

[Water deficiency co-treated with Diclofenac] results in decreased activity of CAT protein; Gum Arabic inhibits the reaction [[Water deficiency co-treated with Diclofenac] results in decreased activity of CAT protein]
[[Particulate Matter co-treated with Water] results in increased abundance of Metals] which results in increased expression of CAT mRNA

PMID:29335169 PMID:31042592

NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060

G

C-C motif chemokine ligand 2

multiple interactions

[Water deficiency co-treated with Diclofenac] results in increased expression of CCL2 protein; Gum Arabic inhibits the reaction [[Water deficiency co-treated with Diclofenac] results in increased expression of CCL2 protein]
[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of CCL2 mRNA; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of CCL2 mRNA]

PMID:31042592 PMID:38705399

NCBI chr17:34,255,285...34,257,203
Ensembl chr17:34,255,274...34,257,208

G

CF transmembrane conductance regulator

multiple interactions

1-Methyl-3-isobutylxanthine promotes the reaction [CFTR protein affects the transport of Water]; CFTR protein promotes the reaction [AQP9 protein affects the transport of Water]; lonidamine inhibits the reaction [CFTR protein promotes the reaction [AQP9 protein affects the transport of Water]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [CFTR protein affects the transport of Water]; Phloretin inhibits the reaction [CFTR protein promotes the reaction [AQP9 protein affects the transport of Water]]

NCBI chr 7:117,480,025...117,668,665
Ensembl chr 7:117,287,120...117,715,971

G

cannabinoid receptor 1

multiple interactions

[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of CNR1 mRNA; [Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of CNR1 protein

NCBI chr 6:88,139,864...88,167,349
Ensembl chr 6:88,139,864...88,166,347

G

collagen type III alpha 1 chain

multiple interactions

[Water deficiency co-treated with Diclofenac] results in increased expression of COL3A1 protein; Gum Arabic inhibits the reaction [[Water deficiency co-treated with Diclofenac] results in increased expression of COL3A1 protein]

NCBI chr 2:188,974,373...189,012,746
Ensembl chr 2:188,974,373...189,012,746

G

complement C3b/C4b receptor 1 like

multiple interactions

[Water deficiency co-treated with Diclofenac] results in decreased expression of CR1L protein; Gum Arabic inhibits the reaction [[Water deficiency co-treated with Diclofenac] results in decreased expression of CR1L protein]

NCBI chr 1:207,645,133...207,723,703
Ensembl chr 1:207,645,113...207,738,416

G

corticotropin releasing hormone

multiple interactions

[AM 251 co-treated with Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of CRH mRNA

NCBI chr 8:66,176,376...66,178,464
Ensembl chr 8:66,176,376...66,178,464

G

cystatin C

multiple interactions

[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of CST3 protein; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of CST3 protein]

NCBI chr20:23,626,706...23,637,955
Ensembl chr20:23,626,706...23,638,473

G

cytochrome P450 family 1 subfamily A member 1

multiple interactions

[[Particulate Matter co-treated with Water] results in increased abundance of Metals] which results in decreased expression of CYP1A1 mRNA

NCBI chr15:74,719,542...74,725,528
Ensembl chr15:74,719,542...74,725,536

G

cytochrome P450 family 2 subfamily E member 1

multiple interactions

[[Particulate Matter co-treated with Water] results in increased abundance of Metals] which results in decreased expression of CYP2E1 mRNA

NCBI chr10:133,527,363...133,539,123
Ensembl chr10:133,520,406...133,561,220

G

endothelin 1

affects export

EDN1 protein affects the export of Water

NCBI chr 6:12,230,516...12,297,194
Ensembl chr 6:12,290,361...12,297,194

G

fibroblast growth factor 2

increases expression

Water results in increased expression of FGF2 mRNA

NCBI chr 4:122,826,682...122,898,236
Ensembl chr 4:122,826,682...122,898,236

G

glutamate-cysteine ligase catalytic subunit

multiple interactions

[[Particulate Matter co-treated with Water] results in increased abundance of Metals] which results in increased expression of GCLC mRNA

NCBI chr 6:53,497,341...53,545,101
Ensembl chr 6:53,497,341...53,616,970

G

glutathione peroxidase 1

multiple interactions

[[Particulate Matter co-treated with Water] results in increased abundance of Metals] which results in increased expression of GPX1 mRNA

NCBI chr 3:49,357,176...49,358,353
Ensembl chr 3:49,357,174...49,358,605

G

glutathione-disulfide reductase

multiple interactions

[[Particulate Matter co-treated with Water] results in increased abundance of Metals] which results in increased expression of GSR mRNA

NCBI chr 8:30,678,066...30,727,846
Ensembl chr 8:30,678,066...30,727,846

G

heparin binding EGF like growth factor

decreases expression

Water results in decreased expression of HBEGF mRNA

NCBI chr 5:140,332,843...140,346,603
Ensembl chr 5:140,332,843...140,346,603

G

hypocretin neuropeptide precursor

multiple interactions

[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of HCRT mRNA; AM 251 inhibits the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of HCRT mRNA]

NCBI chr17:42,184,060...42,185,452
Ensembl chr17:42,184,060...42,185,452

G

high mobility group box 1

multiple interactions

[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of HMGB1 protein; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of HMGB1 protein]

NCBI chr13:30,456,704...30,617,597
Ensembl chr13:30,456,704...30,617,597

G

heme oxygenase 1

increases expression
multiple interactions

Water deficiency results in increased expression of HMOX1 protein
[[Particulate Matter co-treated with Water] results in increased abundance of Metals] which results in increased expression of HMOX1 mRNA

PMID:22060896 PMID:29335169

NCBI chr22:35,381,096...35,394,207
Ensembl chr22:35,380,361...35,394,214

G

hematopoietic prostaglandin D synthase

multiple interactions

Water affects the reaction [Isoquinolines analog binds to and results in decreased activity of HPGDS protein]

NCBI chr 4:94,298,535...94,342,836
Ensembl chr 4:94,298,535...94,342,876

G

interleukin 10

multiple interactions

[Gum Arabic co-treated with Water deficiency co-treated with Diclofenac] results in increased expression of IL10 protein

NCBI chr 1:206,767,602...206,772,494
Ensembl chr 1:206,767,602...206,774,541

G

interleukin 1 beta

multiple interactions

[Water deficiency co-treated with Diclofenac] results in increased expression of IL1B protein; Gum Arabic inhibits the reaction [[Water deficiency co-treated with Diclofenac] results in increased expression of IL1B protein]
[[Particulate Matter co-treated with Water] results in increased abundance of Metals] which results in increased expression of IL1B mRNA; [Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of IL1B mRNA; [Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of IL1B protein; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of IL1B mRNA]; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of IL1B protein]

PMID:29335169 PMID:31042592 PMID:38705399

NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816

G

interleukin 6

multiple interactions

[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of IL6 mRNA; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of IL6 mRNA]

NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002

G

metallothionein 2A

multiple interactions

[[Particulate Matter co-treated with Water] results in increased abundance of Metals] which affects the expression of MT2 mRNA

NCBI chr16:56,608,584...56,609,497
Ensembl chr16:56,608,584...56,609,497

G

NFE2 like bZIP transcription factor 2

multiple interactions

[[Particulate Matter co-treated with Water] results in increased abundance of Metals] which results in increased expression of NFE2L2 mRNA

NCBI chr 2:177,230,303...177,264,727
Ensembl chr 2:177,218,667...177,392,756

G

NLR family pyrin domain containing 3

multiple interactions

[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of NLRP3 mRNA; [Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of NLRP3 protein; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of NLRP3 mRNA]; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of NLRP3 protein]

NCBI chr 1:247,416,077...247,448,817
Ensembl chr 1:247,332,331...247,449,108

G

nitric oxide synthase 2

multiple interactions

[[Particulate Matter co-treated with Water] results in increased abundance of Metals] which results in increased expression of NOS2 mRNA

NCBI chr17:27,756,766...27,800,529
Ensembl chr17:27,756,766...27,800,529

G

neuropeptide Y

multiple interactions

[AM 251 co-treated with Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of NPY mRNA

NCBI chr 7:24,284,190...24,291,862
Ensembl chr 7:24,284,188...24,291,862

G

NAD(P)H quinone dehydrogenase 1

multiple interactions

[[Particulate Matter co-treated with Water] results in increased abundance of Metals] which results in increased expression of NQO1 mRNA

NCBI chr16:69,709,401...69,726,560
Ensembl chr16:69,706,996...69,726,668

G

oxytocin/neurophysin I prepropeptide

multiple interactions

[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of OXT mRNA; [Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased secretion of OXT protein; AM 251 promotes the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of OXT mRNA]; arachidonyl-2-chloroethylamide inhibits the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of OXT mRNA]; arachidonyl-2-chloroethylamide inhibits the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased secretion of OXT protein]

NCBI chr20:3,071,620...3,072,517
Ensembl chr20:3,071,620...3,072,517

G

pro-melanin concentrating hormone

multiple interactions

[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of PMCH mRNA; arachidonyl-2-chloroethylamide promotes the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of PMCH mRNA]

NCBI chr12:102,196,459...102,197,833
Ensembl chr12:102,196,459...102,197,833

G

proopiomelanocortin

multiple interactions

[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of POMC mRNA; AM 251 promotes the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of POMC mRNA]; arachidonyl-2-chloroethylamide inhibits the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of POMC mRNA]

NCBI chr 2:25,160,860...25,168,580
Ensembl chr 2:25,160,853...25,168,903

G

PYD and CARD domain containing

multiple interactions

[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of PYCARD mRNA; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of PYCARD mRNA]

NCBI chr16:31,201,486...31,202,760
Ensembl chr16:31,201,486...31,203,450

G

solute carrier family 12 member 1

multiple interactions
increases import

[Glucose results in increased activity of SLC12A1 protein] which results in increased import of Water; [Mannitol results in increased activity of SLC12A1 protein] which results in increased import of Water
SLC12A1 protein results in increased import of Water

NCBI chr15:48,206,302...48,304,078
Ensembl chr15:48,178,438...48,304,078

G

solute carrier family 5 member 3

increases expression

Water deficiency results in increased expression of SLC5A3 mRNA

NCBI chr21:34,073,578...34,106,260
Ensembl chr21:34,073,578...34,106,260

G

superoxide dismutase 1

multiple interactions

[[Particulate Matter co-treated with Water] results in increased abundance of Metals] which results in increased expression of SOD1 mRNA

NCBI chr21:31,659,693...31,668,931
Ensembl chr21:31,659,666...31,668,931

G

superoxide dismutase 2

increases expression
multiple interactions

Water deficiency results in increased expression of SOD2 protein
[[Particulate Matter co-treated with Water] results in increased abundance of Metals] which results in increased expression of SOD2 mRNA

PMID:22718889 PMID:29335169

NCBI chr 6:159,669,069...159,762,281
Ensembl chr 6:159,669,069...159,762,529

G

sequestosome 1

multiple interactions

[Berberine co-treated with Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of SQSTM1 protein

NCBI chr 5:179,806,393...179,838,078
Ensembl chr 5:179,806,398...179,838,078

G

tachykinin precursor 1

multiple interactions

TAC1 protein alternative form inhibits the reaction [Cholera Toxin results in increased secretion of Water]; TAC1 protein inhibits the reaction [Cholera Toxin results in increased secretion of Water]

NCBI chr 7:97,732,086...97,740,472
Ensembl chr 7:97,732,084...97,740,472

G

tumor necrosis factor

multiple interactions

[Water deficiency co-treated with Diclofenac] results in increased expression of TNF protein; Gum Arabic inhibits the reaction [[Water deficiency co-treated with Diclofenac] results in increased expression of TNF protein]
[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of TNF mRNA; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of TNF mRNA]

PMID:31042592 PMID:38705399

NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336

enalaprilat dihydrate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

angiotensin I converting enzyme

multiple interactions

Enalaprilat inhibits the reaction [Glucose results in increased expression of ACE protein]

NCBI chr17:63,477,061...63,498,373
Ensembl chr17:63,477,061...63,498,380

G

adrenoceptor beta 1

affects expression

Enalaprilat affects the expression of ADRB1 protein

NCBI chr10:114,043,866...114,046,904
Ensembl chr10:114,043,866...114,046,904

G

adrenoceptor beta 2

affects expression

Enalaprilat affects the expression of ADRB2 protein

NCBI chr 5:148,826,611...148,828,623
Ensembl chr 5:148,826,611...148,828,623

G

angiotensinogen

decreases expression
multiple interactions

Enalaprilat results in decreased expression of AGT protein modified form
Enalaprilat inhibits the reaction [Glucose results in increased expression of AGT protein]

PMID:16452552 PMID:21795644

NCBI chr 1:230,702,523...230,745,583
Ensembl chr 1:230,690,776...230,745,576

G

angiotensin II receptor type 1

multiple interactions

Enalaprilat inhibits the reaction [Glucose results in increased expression of AGTR1 protein]

NCBI chr 3:148,697,903...148,743,003
Ensembl chr 3:148,697,784...148,743,008

G

BCL2 apoptosis regulator

increases expression

Enalaprilat results in increased expression of BCL2 mRNA

NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128

G

bradykinin receptor B1

multiple interactions
increases activity

bradykinin, Lys-Leu(8)-desArg(9)- inhibits the reaction [Enalaprilat results in increased activity of BDKRB1 protein]; Zinc affects the reaction [Enalaprilat results in increased activity of BDKRB1 protein]

NCBI chr14:96,256,210...96,264,763
Ensembl chr14:96,256,210...96,268,967

G

endothelin 1

decreases secretion

Enalaprilat results in decreased secretion of EDN1 protein

NCBI chr 6:12,230,516...12,297,194
Ensembl chr 6:12,290,361...12,297,194

G

fibronectin 1

decreases expression
multiple interactions

Enalaprilat results in decreased expression of FN1 mRNA; Enalaprilat results in decreased expression of FN1 protein
Enalaprilat inhibits the reaction [Glucose results in increased expression of FN1 mRNA]

PMID:14520012 PMID:21795644

NCBI chr 2:215,360,865...215,436,068
Ensembl chr 2:215,360,440...215,436,073

G

glutamate dehydrogenase 1

multiple interactions

Enalaprilat inhibits the reaction [Dexamethasone results in decreased expression of GLUD1 mRNA]

NCBI chr10:87,050,202...87,094,843
Ensembl chr10:87,050,202...87,094,843

G

glutamate metabotropic receptor 1

multiple interactions

Enalaprilat inhibits the reaction [Dexamethasone results in increased expression of GRM1 mRNA]

NCBI chr 6:146,027,707...146,437,601
Ensembl chr 6:146,027,646...146,437,601

G

high mobility group box 1

multiple interactions

Enalaprilat inhibits the reaction [Dexamethasone results in increased expression of HMGB1 mRNA]; Enalaprilat inhibits the reaction [Dexamethasone results in increased expression of HMGB1 protein]

NCBI chr13:30,456,704...30,617,597
Ensembl chr13:30,456,704...30,617,597

G

insulin

multiple interactions

Enalaprilat inhibits the reaction [Glucose results in decreased secretion of INS protein]

NCBI chr11:2,159,779...2,161,209
Ensembl chr11:2,159,779...2,161,221

G

peroxisome proliferator activated receptor delta

multiple interactions

[Enalaprilat co-treated with Daunorubicin] results in increased expression of PPARD mRNA

NCBI chr 6:35,342,558...35,428,178
Ensembl chr 6:35,342,558...35,428,191

G

renin

increases expression

Enalaprilat results in increased expression of REN mRNA

NCBI chr 1:204,154,819...204,166,337
Ensembl chr 1:204,154,819...204,190,324

G

serpin family E member 1

decreases expression

Enalaprilat results in decreased expression of SERPINE1 mRNA

NCBI chr 7:101,127,104...101,139,247
Ensembl chr 7:101,127,104...101,139,247

G

solute carrier family 22 member 11

increases uptake

SLC22A11 protein results in increased uptake of Enalaprilat

NCBI chr11:64,555,941...64,572,875
Ensembl chr11:64,555,690...64,572,875

G

solute carrier family 22 member 8

multiple interactions
increases uptake

verlukast inhibits the reaction [SLC22A8 protein results in increased uptake of Enalaprilat]

NCBI chr11:62,992,824...63,015,841
Ensembl chr11:62,989,154...63,015,841

G

solute carrier organic anion transporter family member 1B1

affects abundance

SLCO1B1 gene polymorphism affects the abundance of Enalaprilat

NCBI chr12:21,131,194...21,239,796
Ensembl chr12:21,131,194...21,239,796

G

transforming growth factor beta 1

decreases expression

Enalaprilat results in decreased expression of TGFB1 mRNA; Enalaprilat results in decreased expression of TGFB1 protein

NCBI chr19:41,330,323...41,353,922
Ensembl chr19:41,301,587...41,353,922

G

toll like receptor 4

multiple interactions

Enalaprilat inhibits the reaction [Dexamethasone results in increased expression of TLR4 mRNA]

NCBI chr 9:117,704,403...117,724,735
Ensembl chr 9:117,704,175...117,724,735

G

tumor necrosis factor

decreases expression

Enalaprilat results in decreased expression of TNF mRNA

NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336

gadodiamide hydrate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

adiponectin, C1Q and collagen domain containing

decreases expression

gadodiamide results in decreased expression of ADIPOQ mRNA; gadodiamide results in decreased expression of ADIPOQ protein

NCBI chr 3:186,842,710...186,858,463
Ensembl chr 3:186,842,704...186,858,463

G

AKT serine/threonine kinase 1

increases phosphorylation
multiple interactions

gadodiamide results in increased phosphorylation of AKT1 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [gadodiamide results in increased phosphorylation of AKT1 protein]

NCBI chr14:104,769,349...104,795,748
Ensembl chr14:104,769,349...104,795,759

G

aldehyde dehydrogenase 1 family member A1

increases expression

gadodiamide results in increased expression of ALDH1A1 mRNA

NCBI chr 9:72,900,671...72,953,053
Ensembl chr 9:72,900,671...73,080,442

G

ankyrin repeat domain 22

increases expression

gadodiamide results in increased expression of ANKRD22 mRNA

NCBI chr10:88,819,896...88,851,844
Ensembl chr10:88,819,896...88,851,844

G

apolipoprotein B mRNA editing enzyme catalytic subunit 3A

increases expression

gadodiamide results in increased expression of APOBEC3A mRNA

NCBI chr22:38,957,609...38,963,184
Ensembl chr22:38,952,741...38,963,184

G

ATM serine/threonine kinase

increases expression

gadodiamide results in increased expression of ATM mRNA

NCBI chr11:108,223,067...108,369,102
Ensembl chr11:108,222,804...108,369,102

G

ATPase phospholipid transporting 8B1

increases expression

gadodiamide results in increased expression of ATP8B1 mRNA

NCBI chr18:57,646,426...57,803,315
Ensembl chr18:57,646,426...57,803,315

G

C-C motif chemokine ligand 2

increases expression
increases secretion

gadodiamide results in increased expression of CCL2 mRNA
gadodiamide results in increased expression of CCL2 mRNA; gadodiamide results in increased expression of CCL2 protein
gadodiamide results in increased secretion of CCL2 protein

PMID:20938346 PMID:20959327

NCBI chr17:34,255,285...34,257,203
Ensembl chr17:34,255,274...34,257,208

G

C-C motif chemokine ligand 4

increases expression

gadodiamide results in increased expression of CCL4 protein

NCBI chr17:36,103,827...36,105,614
Ensembl chr17:36,103,827...36,105,621

G

C-C motif chemokine ligand 7

increases expression

gadodiamide results in increased expression of CCL7 protein

NCBI chr17:34,270,221...34,272,242
Ensembl chr17:34,270,221...34,272,242

G

C-C motif chemokine ligand 8

increases expression
increases secretion

gadodiamide results in increased expression of CCL8 mRNA
gadodiamide results in increased secretion of CCL8 protein

NCBI chr17:34,319,435...34,321,402
Ensembl chr17:34,319,435...34,321,402

G

CD1c molecule

increases expression

gadodiamide results in increased expression of CD1C mRNA

NCBI chr 1:158,289,923...158,294,774
Ensembl chr 1:158,289,923...158,294,774

G

centrosomal protein 15

increases expression

gadodiamide results in increased expression of CEP15 mRNA

NCBI chr 3:62,319,022...62,336,213
Ensembl chr 3:62,319,015...62,336,213

G

C-X-C motif chemokine ligand 10

increases expression
increases secretion

gadodiamide results in increased expression of CXCL10 mRNA
gadodiamide results in increased expression of CXCL10 protein
gadodiamide results in increased secretion of CXCL10 protein

PMID:20938346 PMID:20959327

NCBI chr 4:76,021,118...76,023,497
Ensembl chr 4:76,021,118...76,023,497

G

C-X-C motif chemokine ligand 11

increases secretion
increases expression

gadodiamide results in increased secretion of CXCL11 protein
gadodiamide results in increased expression of CXCL11 mRNA

NCBI chr 4:76,033,682...76,036,070
Ensembl chr 4:76,033,682...76,041,415

G

C-X-C motif chemokine ligand 12

increases expression

gadodiamide results in increased expression of CXCL12 mRNA

NCBI chr10:44,370,165...44,385,097
Ensembl chr10:44,370,165...44,386,493

G

C-X-C motif chemokine ligand 9

increases expression

gadodiamide results in increased expression of CXCL9 mRNA

NCBI chr 4:76,001,275...76,007,509
Ensembl chr 4:76,001,275...76,007,509

G

fatty acid binding protein 4

decreases expression

gadodiamide results in decreased expression of FABP4 mRNA; gadodiamide results in decreased expression of FABP4 protein

NCBI chr 8:81,478,419...81,483,233
Ensembl chr 8:81,478,419...81,483,236

G

indoleamine 2,3-dioxygenase 1

increases expression

gadodiamide results in increased expression of IDO1 mRNA

NCBI chr 8:39,913,891...39,928,790
Ensembl chr 8:39,902,275...39,928,790

G

interferon induced protein 44 like

increases expression

gadodiamide results in increased expression of IFI44L mRNA

NCBI chr 1:78,620,448...78,646,145
Ensembl chr 1:78,619,902...78,646,145

G

interferon induced protein with tetratricopeptide repeats 1

increases expression

gadodiamide results in increased expression of IFIT1 mRNA

NCBI chr10:89,392,623...89,406,487
Ensembl chr10:89,392,546...89,406,487

G

interferon induced protein with tetratricopeptide repeats 3

increases expression

gadodiamide results in increased expression of IFIT3 mRNA

NCBI chr10:89,327,997...89,340,968
Ensembl chr10:89,327,307...89,377,473

G

interferon gamma

increases expression

gadodiamide results in increased expression of IFNG mRNA; gadodiamide results in increased expression of IFNG protein

NCBI chr12:68,154,768...68,159,740
Ensembl chr12:68,154,768...68,159,740

G

interleukin 13

increases expression

gadodiamide results in increased expression of IL13 mRNA; gadodiamide results in increased expression of IL13 protein

NCBI chr 5:132,656,522...132,661,110
Ensembl chr 5:132,656,263...132,661,110

G

interleukin 1 alpha

increases expression

gadodiamide results in increased expression of IL1A protein

NCBI chr 2:112,773,925...112,784,493
Ensembl chr 2:112,773,925...112,784,493

G

interleukin 4

increases expression
affects expression

gadodiamide results in increased expression of IL4 protein
gadodiamide affects the expression of IL4 mRNA

NCBI chr 5:132,673,989...132,682,678
Ensembl chr 5:132,673,986...132,682,678

G

interleukin 4 induced 1

increases expression

gadodiamide results in increased expression of IL4I1 mRNA

NCBI chr19:49,889,654...49,929,504
Ensembl chr19:49,889,654...49,929,539

G

interleukin 6

affects expression
increases expression

gadodiamide affects the expression of IL6 protein
gadodiamide results in increased expression of IL6 mRNA

NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002

G

KIT ligand

increases expression

gadodiamide results in increased expression of KITLG protein

NCBI chr12:88,492,793...88,580,471
Ensembl chr12:88,492,793...88,580,851

G

mitogen-activated protein kinase 1

multiple interactions
increases phosphorylation

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [gadodiamide results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [gadodiamide results in increased phosphorylation of MAPK1 protein]

NCBI chr22:21,759,657...21,867,680
Ensembl chr22:21,759,657...21,867,680

G

mitogen-activated protein kinase 3

multiple interactions
increases phosphorylation

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [gadodiamide results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [gadodiamide results in increased phosphorylation of MAPK3 protein]

NCBI chr16:30,114,105...30,123,220
Ensembl chr16:30,114,105...30,123,506

G

matrix metallopeptidase 1

multiple interactions
increases expression

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [gadodiamide results in increased expression of MMP1 protein]; U 0126 inhibits the reaction [gadodiamide results in increased expression of MMP1 protein]
gadodiamide results in increased expression of MMP1 mRNA; gadodiamide results in increased expression of MMP1 protein

NCBI chr11:102,789,919...102,798,160
Ensembl chr11:102,789,401...102,798,160

G

nitric oxide synthase 2

increases expression

gadodiamide results in increased expression of NOS2 protein

NCBI chr17:27,756,766...27,800,529
Ensembl chr17:27,756,766...27,800,529

G

neurexophilin and PC-esterase domain family member 3

increases expression

gadodiamide results in increased expression of NXPE3 mRNA

NCBI chr 3:101,779,211...101,828,231
Ensembl chr 3:101,779,177...101,843,743

G

peroxisome proliferator activated receptor gamma

decreases expression

gadodiamide results in decreased expression of PPARG mRNA; gadodiamide results in decreased expression of PPARG protein

NCBI chr 3:12,287,368...12,434,344
Ensembl chr 3:12,287,368...12,434,356

G

RELA proto-oncogene, NF-kB subunit

increases localization

gadodiamide results in increased localization of RELA protein

NCBI chr11:65,653,601...65,663,857
Ensembl chr11:65,653,599...65,663,090

G

ras homolog family member Q

increases expression

gadodiamide results in increased expression of RHOQ mRNA

NCBI chr 2:46,542,490...46,584,688
Ensembl chr 2:46,541,806...46,584,688

G

Ras like without CAAX 1

increases expression

gadodiamide results in increased expression of RIT1 mRNA

NCBI chr 1:155,897,808...155,911,349
Ensembl chr 1:155,897,808...155,911,404

G

ring finger protein 125

increases expression

gadodiamide results in increased expression of RNF125 mRNA

NCBI chr18:32,018,825...32,088,144
Ensembl chr18:32,018,825...32,073,219

G

radical S-adenosyl methionine domain containing 2

increases expression

gadodiamide results in increased expression of RSAD2 mRNA

NCBI chr 2:6,865,885...6,898,239
Ensembl chr 2:6,865,557...6,898,239

G

solute carrier family 39 member 10

increases expression

gadodiamide results in increased expression of SLC39A10 mRNA

NCBI chr 2:195,613,029...195,737,700
Ensembl chr 2:195,575,977...195,737,702

G

sialophorin

increases expression

gadodiamide results in increased expression of SPN mRNA

NCBI chr16:29,662,963...29,670,876
Ensembl chr16:29,662,979...29,670,876

G

secreted phosphoprotein 1

increases expression

gadodiamide results in increased expression of SPP1 protein

NCBI chr 4:87,975,714...87,983,411
Ensembl chr 4:87,975,667...87,983,532

G

transforming growth factor beta 1

increases expression

gadodiamide results in increased expression of TGFB1 mRNA; gadodiamide results in increased expression of TGFB1 protein

PMID:19404939 PMID:20938346

NCBI chr19:41,330,323...41,353,922
Ensembl chr19:41,301,587...41,353,922

G

TIMP metallopeptidase inhibitor 1

increases expression
multiple interactions

gadodiamide results in increased expression of TIMP1 mRNA; gadodiamide results in increased expression of TIMP1 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [gadodiamide results in increased expression of TIMP1 protein]; U 0126 inhibits the reaction [gadodiamide results in increased expression of TIMP1 protein]

PMID:19561517 PMID:20938346

NCBI chr X:47,582,436...47,586,789
Ensembl chr X:47,582,408...47,586,789

G

ubiquitin D

increases expression

gadodiamide results in increased expression of UBD mRNA

NCBI chr 6:29,555,515...29,559,732
Ensembl chr 6:29,555,515...29,559,732

G

vascular endothelial growth factor A

increases expression

gadodiamide results in increased expression of VEGFA mRNA; gadodiamide results in increased expression of VEGFA protein

PMID:19404939 PMID:20938346

NCBI chr 6:43,770,211...43,786,487
Ensembl chr 6:43,770,184...43,786,487

G

WD repeat domain 5

increases expression

gadodiamide results in increased expression of WDR5 mRNA

NCBI chr 9:134,135,199...134,159,968
Ensembl chr 9:134,135,365...134,159,968

G

X-linked inhibitor of apoptosis

increases expression

gadodiamide results in increased expression of XIAP mRNA

NCBI chr X:123,859,708...123,913,972
Ensembl chr X:123,859,712...123,913,972

G

zinc finger protein 595

increases expression

gadodiamide results in increased expression of ZNF595 mRNA

NCBI chr 4:53,321...88,208
Ensembl chr 4:53,286...88,208

G

zinc finger protein 652

increases expression

gadodiamide results in increased expression of ZNF652 mRNA

NCBI chr17:49,288,117...49,362,473
Ensembl chr17:49,289,206...49,362,473

hydroxyl

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acyl-CoA binding domain containing 3

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of ACBD3-AS1 mRNA] which results in increased expression of ACBD3 mRNA

NCBI chr 1:226,144,679...226,186,741
Ensembl chr 1:226,144,679...226,186,741

G

ACBD3 antisense RNA 1

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of ACBD3-AS1 mRNA] which results in increased expression of ACBD3 mRNA; [Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of ACBD3-AS1 mRNA

NCBI chr 1:226,148,003...226,154,977
Ensembl chr 1:226,148,003...226,155,071

G

aconitase 2

multiple interactions

[[[Superoxides results in decreased activity of ACO2 protein] which results in increased abundance of Iron] which co-treated with Hydrogen Peroxide] results in increased chemical synthesis of Hydroxyl Radical

NCBI chr22:41,469,117...41,528,974
Ensembl chr22:41,447,830...41,529,273

G

ankyrin and armadillo repeat containing

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of OSGEPL1-AS1 mRNA] which results in increased expression of ANKAR mRNA

NCBI chr 2:189,674,670...189,763,059
Ensembl chr 2:189,674,290...189,761,193

G

ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 1

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of ARAP1-AS1 mRNA] which results in increased expression of ARAP1 mRNA

NCBI chr11:72,685,069...72,752,408
Ensembl chr11:72,685,069...72,793,599

G

ARAP1 antisense RNA 1

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of ARAP1-AS1 mRNA] which results in increased expression of ARAP1 mRNA; [Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of ARAP1-AS1 mRNA

Ensembl chr11:72,685,075...72,693,808

G

catalase

decreases response to substance
multiple interactions

CAT protein results in decreased susceptibility to Hydroxyl Radical
CAT protein inhibits the reaction [chromium hexavalent ion results in increased chemical synthesis of Hydroxyl Radical]

PMID:10421593 PMID:11678602

NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060

G

ciliogenesis associated TTC17 interacting protein

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of CATIP-AS1 mRNA] which results in increased expression of CATIP mRNA

NCBI chr 2:218,356,857...218,368,094
Ensembl chr 2:218,356,857...218,368,099

G

CATIP antisense RNA 1

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of CATIP-AS1 mRNA] which results in increased expression of CATIP mRNA; [Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of CATIP-AS1 mRNA

NCBI chr 2:218,366,665...218,367,902
Ensembl chr 2:218,366,661...218,367,885

G

cobalamin binding intrinsic factor

affects metabolic processing

CBLIF protein affects the metabolism of Hydroxyl Radical

NCBI chr11:59,829,273...59,845,499
Ensembl chr11:59,829,273...59,845,499

G

coiled-coil domain containing 183

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of CCDC183-AS1 mRNA] which results in increased expression of CCDC183 mRNA

NCBI chr 9:136,796,338...136,807,741
Ensembl chr 9:136,796,338...136,807,741

G

CCDC183 antisense RNA 1

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of CCDC183-AS1 mRNA] which results in increased expression of CCDC183 mRNA; [Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of CCDC183-AS1 mRNA

NCBI chr 9:136,803,927...136,808,848
Ensembl chr 9:136,803,927...136,808,848

G

ciliary microtubule associated protein 1C

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of DNM1P35 mRNA] which results in increased expression of CIMAP1C mRNA

NCBI chr15:75,724,041...75,727,688
Ensembl chr15:75,724,041...75,727,688

G

collagen type IV alpha 2 chain

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in decreased expression of COL4A2-AS1 mRNA] which results in decreased expression of COL4A2 mRNA

NCBI chr13:110,307,284...110,513,209
Ensembl chr13:110,305,812...110,513,209

G

COL4A2 antisense RNA 1

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in decreased expression of COL4A2-AS1 mRNA] which results in decreased expression of COL4A2 mRNA; [Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in decreased expression of COL4A2-AS1 mRNA

NCBI chr13:110,502,576...110,508,179
Ensembl chr13:110,502,575...110,508,179

G

coronin 1A

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in decreased expression of CORO1A-AS1 mRNA] which results in decreased expression of CORO1A mRNA

NCBI chr16:30,183,602...30,189,076
Ensembl chr16:30,182,827...30,189,076

G

CORO1A antisense RNA 1

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in decreased expression of CORO1A-AS1 mRNA] which results in decreased expression of CORO1A mRNA; [Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in decreased expression of CORO1A-AS1 mRNA

NCBI chr16:30,183,393...30,184,788

G

CSRP3 and E2F8 antisense RNA 1

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of CSRP3-AS1 mRNA] which results in increased expression of E2F8 mRNA; [Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of CSRP3-AS1 mRNA

NCBI chr11:19,196,713...19,313,258
Ensembl chr11:19,196,775...19,281,426

G

dicarbonyl and L-xylulose reductase

increases chemical synthesis
multiple interactions

DCXR protein results in increased chemical synthesis of Hydroxyl Radical
[DCXR protein results in increased metabolism of 9,10-phenanthrenequinone] which results in increased chemical synthesis of Hydroxyl Radical

NCBI chr17:82,035,858...82,037,697
Ensembl chr17:82,035,136...82,037,709

G

DNA damage inducible transcript 4

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in decreased expression of DDIT4-AS1 mRNA] which results in decreased expression of DDIT4 mRNA

NCBI chr10:72,273,924...72,276,036
Ensembl chr10:72,273,919...72,276,036

G

DDIT4 antisense RNA 1

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in decreased expression of DDIT4-AS1 mRNA] which results in decreased expression of DDIT4 mRNA; [Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in decreased expression of DDIT4-AS1 mRNA

NCBI chr10:72,271,386...72,273,711
Ensembl chr10:72,274,915...72,275,980

G

DEAD-box helicase 59

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of DDX59-AS1 mRNA] which results in increased expression of DDX59 mRNA

NCBI chr 1:200,640,805...200,669,907
Ensembl chr 1:200,623,896...200,669,907

G

DDX59 antisense RNA 1

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of DDX59-AS1 mRNA] which results in increased expression of DDX59 mRNA; [Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of DDX59-AS1 mRNA

NCBI chr 1:200,669,507...200,694,250
Ensembl chr 1:200,669,507...200,694,250

G

DLG associated protein 1

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of DLGAP1-AS2 mRNA] which results in increased expression of DLGAP1 mRNA

NCBI chr18:3,496,032...4,455,307
Ensembl chr18:3,496,032...4,455,307

G

DLGAP1 antisense RNA 2

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of DLGAP1-AS2 mRNA] which results in increased expression of DLGAP1 mRNA; [Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of DLGAP1-AS2 mRNA

NCBI chr18:3,603,737...3,610,089
Ensembl chr18:3,594,114...3,610,103

G

dynamin 1 pseudogene 35

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of DNM1P35 mRNA] which results in increased expression of CIMAP1C mRNA; [Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of DNM1P35 mRNA

NCBI chr15:75,727,670...75,740,077
Ensembl chr15:75,727,670...75,738,629

G

DNA methyltransferase 3 like

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of DNMT3L-AS1 mRNA] which results in increased expression of DNMT3L mRNA

NCBI chr21:44,246,339...44,261,897
Ensembl chr21:44,246,339...44,262,216

G

DNMT3L antisense RNA 1

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of DNMT3L-AS1 mRNA] which results in increased expression of DNMT3L mRNA; [[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of DNMT3L-AS1 mRNA] which results in increased expression of ICOSLG mRNA; [Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of DNMT3L-AS1 mRNA

NCBI chr21:44,250,813...44,251,521
Ensembl chr21:44,250,813...44,251,520

G

dedicator of cytokinesis 3

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of LINC02019 mRNA] which results in increased expression of DOCK3 mRNA

NCBI chr 3:50,674,927...51,384,198
Ensembl chr 3:50,674,927...51,384,198

G

dynein light chain Tctex-type 2B

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in decreased expression of TM4SF19-AS1 mRNA] which results in increased expression of DYNLT2B mRNA

NCBI chr 3:196,291,219...196,318,240
Ensembl chr 3:196,291,219...196,318,299

G

E2F transcription factor 8

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of CSRP3-AS1 mRNA] which results in increased expression of E2F8 mRNA

NCBI chr11:19,224,063...19,241,655
Ensembl chr11:19,224,063...19,241,620

G

family with sequence similarity 83 member F

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of TNRC6B-DT mRNA] which results in increased expression of FAM83F mRNA

NCBI chr22:39,994,954...40,043,534
Ensembl chr22:39,994,954...40,043,534

G

F-box and WD repeat domain containing 7

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of FBXW7-AS1 mRNA] which results in increased expression of FBXW7 mRNA

NCBI chr 4:152,320,544...152,536,092
Ensembl chr 4:152,320,544...152,536,092

G

FBXW7 antisense RNA 1

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of FBXW7-AS1 mRNA] which results in increased expression of FBXW7 mRNA; [Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of FBXW7-AS1 mRNA

NCBI chr 4:152,337,674...152,338,096
Ensembl chr 4:152,337,655...152,338,098

G

forkhead associated phosphopeptide binding domain 1

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of FHAD1-AS1 mRNA] which results in increased expression of FHAD1 mRNA

NCBI chr 1:15,236,521...15,403,010
Ensembl chr 1:15,236,521...15,400,283

G

FHAD1 antisense RNA 1

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of FHAD1-AS1 mRNA] which results in increased expression of FHAD1 mRNA; [Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of FHAD1-AS1 mRNA

NCBI chr 1:15,326,680...15,343,883
Ensembl chr 1:15,326,680...15,343,876

G

filamin B

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in decreased expression of FLNB-AS1 mRNA] which results in decreased expression of FLNB mRNA

NCBI chr 3:58,008,422...58,172,251
Ensembl chr 3:58,008,398...58,172,251

G

FLNB antisense RNA 1

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in decreased expression of FLNB-AS1 mRNA] which results in decreased expression of FLNB mRNA; [Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in decreased expression of FLNB-AS1 mRNA

NCBI chr 3:58,162,547...58,170,635
Ensembl chr 3:58,162,547...58,170,636

G

filamin C

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of FLNC-AS1 mRNA] which results in increased expression of FLNC mRNA

NCBI chr 7:128,830,406...128,859,272
Ensembl chr 7:128,830,406...128,859,274

G

FLNC antisense RNA 1

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of FLNC-AS1 mRNA] which results in increased expression of FLNC mRNA; [Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of FLNC-AS1 mRNA

NCBI chr 7:128,850,162...128,862,626
Ensembl chr 7:128,850,162...128,862,626

G

fragile X messenger ribonucleoprotein 1

increases abundance
multiple interactions

FMR1 5' UTR mutant form results in increased abundance of Hydroxyl Radical
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone inhibits the reaction [FMR1 5' UTR mutant form results in increased abundance of Hydroxyl Radical]

NCBI chr X:147,911,919...147,951,125
Ensembl chr X:147,911,919...147,951,125

G

forkhead box C2

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in decreased expression of FOXC2-AS1 mRNA] which results in decreased expression of FOXC2 mRNA

NCBI chr16:86,566,829...86,569,728
Ensembl chr16:86,566,829...86,569,728

G

FOXC2 antisense RNA 1

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in decreased expression of FOXC2-AS1 mRNA] which results in decreased expression of FOXC2 mRNA; [Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in decreased expression of FOXC2-AS1 mRNA

NCBI chr16:86,565,145...86,567,761
Ensembl chr16:86,565,145...86,567,847

G

forkhead box L2

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of LINC01391 mRNA] which results in increased expression of FOXL2 mRNA

NCBI chr 3:138,944,224...138,947,137
Ensembl chr 3:138,944,224...138,947,137

G

GRIP and coiled-coil domain containing 2

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of GCC2-AS1 mRNA] which results in increased expression of GCC2 mRNA

NCBI chr 2:108,449,206...108,509,415
Ensembl chr 2:108,449,107...108,509,415

G

GCC2 antisense RNA 1

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of GCC2-AS1 mRNA] which results in increased expression of GCC2 mRNA; [Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of GCC2-AS1 mRNA

NCBI chr 2:108,507,527...108,534,219
Ensembl chr 2:108,507,515...108,534,196

G

glycerol kinase

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of GK-AS1 mRNA] which results in increased expression of GK mRNA; [[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of GK-IT1 mRNA] which results in increased expression of GK mRNA

NCBI chr X:30,653,423...30,731,462
Ensembl chr X:30,653,359...30,731,462

G

GK antisense RNA 1

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of GK-AS1 mRNA] which results in increased expression of GK mRNA; [Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of GK-AS1 mRNA

NCBI chr X:30,700,064...30,718,099
Ensembl chr X:30,699,998...30,724,174

G

GK intronic transcript 1

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of GK-IT1 mRNA] which results in increased expression of GK mRNA; [Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of GK-IT1 mRNA

Ensembl chr X:30,671,635...30,672,166

G

gelsolin

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in decreased expression of GSN-AS1 mRNA] which results in decreased expression of GSN mRNA

NCBI chr 9:121,201,483...121,332,842
Ensembl chr 9:121,207,794...121,332,843

G

GSN antisense RNA 1

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in decreased expression of GSN-AS1 mRNA] which results in decreased expression of GSN mRNA; [Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in decreased expression of GSN-AS1 mRNA

NCBI chr 9:121,280,768...121,285,530
Ensembl chr 9:121,280,768...121,285,530

G

HOXB cluster antisense RNA 4

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of HOXB-AS4 mRNA] which results in increased expression of HOXB9 mRNA; [Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of HOXB-AS4 mRNA

NCBI chr17:48,628,698...48,634,932
Ensembl chr17:48,628,675...48,634,932

G

homeobox B9

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of HOXB-AS4 mRNA] which results in increased expression of HOXB9 mRNA

NCBI chr17:48,621,156...48,626,358
Ensembl chr17:48,621,156...48,626,358

G

homeobox C13

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of HOXC13-AS mRNA] which results in increased expression of HOXC13 mRNA

NCBI chr12:53,938,831...53,946,544
Ensembl chr12:53,938,831...53,946,544

G

HOXC13 antisense RNA

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of HOXC13-AS mRNA] which results in increased expression of HOXC13 mRNA; [Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of HOXC13-AS mRNA

NCBI chr12:53,935,328...53,939,643
Ensembl chr12:53,935,328...53,939,643

G

HRas proto-oncogene, GTPase

multiple interactions

HRAS protein promotes the reaction [[sodium bichromate results in increased abundance of chromium hexavalent ion] which results in increased abundance of Hydroxyl Radical]; Oxygen deficiency inhibits the reaction [HRAS protein promotes the reaction [[sodium bichromate results in increased abundance of chromium hexavalent ion] which results in increased abundance of Hydroxyl Radical]]

NCBI chr11:532,242...535,576
Ensembl chr11:532,242...537,321

G

islet amyloid polypeptide

multiple interactions

IAPP protein promotes the reaction [[Copper co-treated with Ascorbic Acid] results in increased abundance of Hydroxyl Radical]

NCBI chr12:21,354,959...21,379,980
Ensembl chr12:21,354,959...21,379,980

G

inducible T cell costimulator ligand

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of DNMT3L-AS1 mRNA] which results in increased expression of ICOSLG mRNA

NCBI chr21:44,216,981...44,240,943
Ensembl chr21:44,215,382...44,241,446

G

insulin induced gene 1

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in decreased expression of INSIG1-DT mRNA] which results in decreased expression of INSIG1 mRNA

NCBI chr 7:155,297,878...155,310,235
Ensembl chr 7:155,297,776...155,310,235

G

INSIG1 divergent transcript

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in decreased expression of INSIG1-DT mRNA] which results in decreased expression of INSIG1 mRNA; [Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in decreased expression of INSIG1-DT mRNA

NCBI chr 7:155,288,596...155,298,980

G

integrin subunit alpha 3

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of PICART1 mRNA] which results in decreased expression of ITGA3 mRNA

NCBI chr17:50,056,110...50,090,481
Ensembl chr17:50,055,968...50,090,481

G

KIAA1614

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of KIAA1614-AS1 mRNA] which results in increased expression of KIAA1614 mRNA

NCBI chr 1:180,912,897...180,951,614
Ensembl chr 1:180,912,897...180,951,614

G

KIAA1614 antisense RNA 1

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of KIAA1614-AS1 mRNA] which results in increased expression of KIAA1614 mRNA; [Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of KIAA1614-AS1 mRNA

NCBI chr 1:180,949,690...180,954,887
Ensembl chr 1:180,949,699...180,954,887

G

keratin 7

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in decreased expression of KRT7-AS mRNA] which results in decreased expression of KRT7 mRNA

NCBI chr12:52,233,243...52,255,853
Ensembl chr12:52,232,520...52,252,186

G

KRT7 antisense RNA 1

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in decreased expression of KRT7-AS mRNA] which results in decreased expression of KRT7 mRNA; [Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in decreased expression of KRT7-AS mRNA

NCBI chr12:52,245,043...52,247,448
Ensembl chr12:52,245,048...52,247,448

G

ladybird homeobox 2

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of LBX2-AS1 mRNA] which results in increased expression of LBX2 mRNA

NCBI chr 2:74,497,517...74,503,316
Ensembl chr 2:74,497,517...74,503,316

G

LBX2 antisense RNA 1

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of LBX2-AS1 mRNA] which results in increased expression of LBX2 mRNA; [[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of LBX2-AS1 mRNA] which results in increased expression of TLX2 mRNA; [Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of LBX2-AS1 mRNA

NCBI chr 2:74,502,593...74,505,065
Ensembl chr 2:74,502,552...74,505,091

G

LIF interleukin 6 family cytokine

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of LIF-AS1 mRNA] which results in increased expression of LIF mRNA

NCBI chr22:30,240,453...30,246,759
Ensembl chr22:30,240,453...30,246,759

G

LIF antisense RNA 1

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of LIF-AS1 mRNA] which results in increased expression of LIF mRNA; [Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of LIF-AS1 mRNA

NCBI chr22:30,239,194...30,240,538
Ensembl chr22:30,239,194...30,240,538

G

long intergenic non-protein coding RNA 1391

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of LINC01391 mRNA] which results in increased expression of FOXL2 mRNA; [Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of LINC01391 mRNA

NCBI chr 3:138,935,189...138,944,020
Ensembl chr 3:138,935,189...138,944,020

G

long intergenic non-protein coding RNA 1786

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of LINC01786 mRNA] which results in increased expression of SCNN1D mRNA; [Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of LINC01786 mRNA

NCBI chr 1:1,274,002...1,280,607
Ensembl chr 1:1,275,223...1,280,420

G

long intergenic non-protein coding RNA 2019

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of LINC02019 mRNA] which results in increased expression of DOCK3 mRNA; [Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of LINC02019 mRNA

NCBI chr 3:50,669,439...50,672,051
Ensembl chr 3:50,669,989...50,672,048

G

lipoprotein(a)

multiple interactions

[[Superoxides co-treated with Hydroxyl Radical] results in increased oxidation of LPA protein] which results in decreased secretion of SERPINE1 protein; [Superoxides co-treated with Hydroxyl Radical] results in increased oxidation of LPA protein

NCBI chr 6:160,531,482...160,664,275
Ensembl chr 6:160,531,482...160,664,275

G

membrane metalloendopeptidase like 1

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of MMEL1-AS1 mRNA] which results in decreased expression of MMEL1 mRNA

NCBI chr 1:2,590,639...2,633,016
Ensembl chr 1:2,590,639...2,633,016

G

MMEL1 antisense RNA 1

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of MMEL1-AS1 mRNA] which results in decreased expression of MMEL1 mRNA

NCBI chr 1:2,628,756...2,636,620

G

macrophage scavenger receptor 1

decreases degradation

Hydroxyl Radical results in decreased degradation of MSR1 mRNA

NCBI chr 8:16,107,881...16,192,651
Ensembl chr 8:16,107,878...16,567,490

G

metallothionein 3

multiple interactions

[[MT3 protein binds to Zinc] which co-treated with Ascorbic Acid] inhibits the reaction [Copper results in increased chemical synthesis of Hydroxyl Radical]

NCBI chr16:56,589,528...56,591,085
Ensembl chr16:56,589,074...56,591,088

G

nerve growth factor receptor

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of NGFR-AS1 mRNA] which results in increased expression of NGFR mRNA

NCBI chr17:49,495,293...49,515,008
Ensembl chr17:49,495,293...49,515,008

G

NGFR antisense RNA 1

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of NGFR-AS1 mRNA] which results in increased expression of NGFR mRNA; [Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of NGFR-AS1 mRNA

NCBI chr17:49,505,657...49,574,064
Ensembl chr17:49,505,657...49,574,064

G

nucleobindin 1

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in decreased expression of NUCB1-AS1 mRNA] which results in decreased expression of NUCB1 mRNA

NCBI chr19:48,900,312...48,923,372
Ensembl chr19:48,900,050...48,923,473

G

NUCB1 antisense RNA 1

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in decreased expression of NUCB1-AS1 mRNA] which results in decreased expression of NUCB1 mRNA; [Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in decreased expression of NUCB1-AS1 mRNA

NCBI chr19:48,910,930...48,918,891
Ensembl chr19:48,910,930...48,918,891

G

ornithine decarboxylase 1

multiple interactions

[ferric nitrilotriacetate results in increased abundance of Hydroxyl Radical] which results in increased activity of ODC1 protein; Active Hexose Correlated Compound inhibits the reaction [[ferric nitrilotriacetate results in increased abundance of Hydroxyl Radical] which results in increased activity of ODC1 protein]

NCBI chr 2:10,439,968...10,448,327
Ensembl chr 2:10,439,968...10,448,327

G

O-sialoglycoprotein endopeptidase like 1

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of OSGEPL1-AS1 mRNA] which results in decreased expression of OSGEPL1 mRNA

NCBI chr 2:189,746,660...189,763,198
Ensembl chr 2:189,746,660...189,763,227

G

OSGEPL1 antisense RNA 1

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of OSGEPL1-AS1 mRNA] which results in decreased expression of OSGEPL1 mRNA; [[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of OSGEPL1-AS1 mRNA] which results in increased expression of ANKAR mRNA; [Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of OSGEPL1-AS1 mRNA

NCBI chr 2:189,762,780...189,765,556
Ensembl chr 2:189,762,704...189,765,556

G

p53 inducible cancer associated RNA transcript 1

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of PICART1 mRNA] which results in decreased expression of ITGA3 mRNA

NCBI chr17:50,050,349...50,055,739
Ensembl chr17:50,050,349...50,055,746

G

piwi like RNA-mediated gene silencing 2

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in decreased expression of PIWIL2-DT mRNA] which results in increased expression of PIWIL2 mRNA

NCBI chr 8:22,275,316...22,357,568
Ensembl chr 8:22,275,316...22,357,568

G

PIWIL2 divergent transcript

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in decreased expression of PIWIL2-DT mRNA] which results in increased expression of PIWIL2 mRNA; [Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in decreased expression of PIWIL2-DT mRNA

NCBI chr 8:22,254,576...22,275,162
Ensembl chr 8:22,254,576...22,275,162

G

phospholipase A2 group IVE

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of PLA2G4E-AS1 mRNA] which results in increased expression of PLA2G4E mRNA

NCBI chr15:41,981,582...42,050,703
Ensembl chr15:41,981,394...42,051,190

G

PLA2G4E antisense RNA 1

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of PLA2G4E-AS1 mRNA] which results in increased expression of PLA2G4E mRNA; [Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of PLA2G4E-AS1 mRNA

NCBI chr15:41,972,763...41,999,094
Ensembl chr15:41,972,763...41,999,094

G

phospholipase C like 2

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of PLCL2-AS1 mRNA] which results in increased expression of PLCL2 mRNA

NCBI chr 3:16,884,955...17,090,606
Ensembl chr 3:16,802,651...17,090,604

G

PLCL2 antisense RNA 1

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of PLCL2-AS1 mRNA] which results in increased expression of PLCL2 mRNA; [Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of PLCL2-AS1 mRNA

NCBI chr 3:17,042,752...17,054,584
Ensembl chr 3:17,042,742...17,044,192

G

DNA polymerase eta

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of POLH-AS1 mRNA] which results in increased expression of POLH mRNA

NCBI chr 6:43,576,185...43,620,523
Ensembl chr 6:43,576,185...43,620,523

G

POLH antisense RNA 1

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of POLH-AS1 mRNA] which results in increased expression of POLH mRNA; [Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of POLH-AS1 mRNA

Ensembl chr 6:43,588,230...43,591,362

G

cytochrome p450 oxidoreductase

multiple interactions

[[Iron co-treated with POR protein] results in increased metabolism of Diquat] which results in increased abundance of Hydroxyl Radical; [[Iron co-treated with POR protein] results in increased metabolism of Paraquat] which results in increased abundance of Hydroxyl Radical; [POR protein results in increased metabolism of Diquat] which results in increased abundance of Hydroxyl Radical
[POR protein results in increased metabolism of Diquat] which results in increased abundance of Hydroxyl Radical; Dimethyl Sulfoxide inhibits the reaction [[POR protein results in increased metabolism of Diquat] which results in increased abundance of Hydroxyl Radical]; diphenyleneiodonium inhibits the reaction [[POR protein results in increased metabolism of Diquat] which results in increased abundance of Hydroxyl Radical]

NCBI chr 7:75,915,155...75,986,855
Ensembl chr 7:75,899,200...75,986,855

G

prickle planar cell polarity protein 2

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of PRICKLE2-AS1 mRNA] which results in increased expression of PRICKLE2 mRNA; [[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of PRICKLE2-AS3 mRNA] which results in increased expression of PRICKLE2 mRNA

NCBI chr 3:64,092,236...64,268,173
Ensembl chr 3:64,092,236...64,445,476

G

PRICKLE2 antisense RNA 1

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of PRICKLE2-AS1 mRNA] which results in increased expression of PRICKLE2 mRNA; [Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of PRICKLE2-AS1 mRNA

NCBI chr 3:64,067,964...64,103,131
Ensembl chr 3:64,067,964...64,103,131
Ensembl chr 3:64,067,964...64,103,131

G

PRICKLE2 antisense RNA 3

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of PRICKLE2-AS3 mRNA] which results in increased expression of PRICKLE2 mRNA; [Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of PRICKLE2-AS3 mRNA

NCBI chr 3:64,187,544...64,201,561
Ensembl chr 3:64,187,544...64,200,965

G

sodium channel epithelial 1 subunit delta

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of LINC01786 mRNA] which results in increased expression of SCNN1D mRNA

NCBI chr 1:1,280,436...1,292,025
Ensembl chr 1:1,280,436...1,292,029

G

serpin family E member 1

multiple interactions

[[Superoxides co-treated with Hydroxyl Radical] results in increased oxidation of LPA protein] which results in decreased secretion of SERPINE1 protein

NCBI chr 7:101,127,104...101,139,247
Ensembl chr 7:101,127,104...101,139,247

G

SH3 domain containing ring finger 3

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in decreased expression of SH3RF3-AS1 mRNA] which results in decreased expression of SH3RF3 mRNA

NCBI chr 2:109,129,205...109,504,634
Ensembl chr 2:109,129,205...109,504,634

G

SH3RF3 antisense RNA 1

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in decreased expression of SH3RF3-AS1 mRNA] which results in decreased expression of SH3RF3 mRNA; [Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in decreased expression of SH3RF3-AS1 mRNA

NCBI chr 2:109,127,327...109,130,119
Ensembl chr 2:109,127,327...109,128,930

G

SMAD family member 5

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of SMAD5-AS1 mRNA] which results in increased expression of SMAD5 mRNA

NCBI chr 5:136,132,845...136,182,733
Ensembl chr 5:136,132,845...136,188,747

G

SMAD5 antisense RNA 1

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of SMAD5-AS1 mRNA] which results in increased expression of SMAD5 mRNA; [Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of SMAD5-AS1 mRNA

NCBI chr 5:136,129,513...136,134,890
Ensembl chr 5:136,129,507...136,134,890

G

synaptophysin

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of SYP-AS1 mRNA] which results in increased expression of SYP mRNA

NCBI chr X:49,187,815...49,200,193
Ensembl chr X:49,187,815...49,200,218

G

SYP antisense RNA 1

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of SYP-AS1 mRNA] which results in increased expression of SYP mRNA; [Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of SYP-AS1 mRNA

NCBI chr X:49,198,839...49,202,454
Ensembl chr X:49,198,966...49,202,454

G

TGF-beta activated kinase 1 (MAP3K7) binding protein 3

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of TAB3-AS1 mRNA] which results in increased expression of TAB3 mRNA; [[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of TAB3-AS2 mRNA] which results in increased expression of TAB3 mRNA

NCBI chr X:30,827,442...30,889,254
Ensembl chr X:30,827,442...30,975,084

G

TAB3 antisense RNA 1

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of TAB3-AS1 mRNA] which results in increased expression of TAB3 mRNA; [Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of TAB3-AS1 mRNA

NCBI chr X:30,834,623...30,839,073
Ensembl chr X:30,834,623...30,835,300

G

TAB3 antisense RNA 2

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of TAB3-AS2 mRNA] which results in increased expression of TAB3 mRNA; [Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of TAB3-AS2 mRNA

Ensembl chr X:30,854,321...30,854,707

G

Thy-1 cell surface antigen

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in decreased expression of THY1-AS1 mRNA] which results in decreased expression of THY1 mRNA

NCBI chr11:119,415,476...119,424,985
Ensembl chr11:119,415,476...119,424,985

G

THY1 antisense RNA 1

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in decreased expression of THY1-AS1 mRNA] which results in decreased expression of THY1 mRNA; [Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in decreased expression of THY1-AS1 mRNA

G

T cell leukemia homeobox 2

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of LBX2-AS1 mRNA] which results in increased expression of TLX2 mRNA

NCBI chr 2:74,514,450...74,517,148
Ensembl chr 2:74,513,463...74,517,148

G

transmembrane 4 L six family member 19

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in decreased expression of TM4SF19-AS1 mRNA] which results in decreased expression of TM4SF19 mRNA

NCBI chr 3:196,323,547...196,338,388
Ensembl chr 3:196,319,342...196,338,503

G

TM4SF19 antisense RNA 1

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in decreased expression of TM4SF19-AS1 mRNA] which results in decreased expression of TM4SF19 mRNA; [[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in decreased expression of TM4SF19-AS1 mRNA] which results in increased expression of DYNLT2B mRNA; [Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in decreased expression of TM4SF19-AS1 mRNA

NCBI chr 3:196,318,332...196,325,570
Ensembl chr 3:196,318,330...196,325,570

G

TNF receptor superfamily member 10a

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of TNFRSF10A-AS1 mRNA] which results in increased expression of TNFRSF10A mRNA

NCBI chr 8:23,190,452...23,225,102
Ensembl chr 8:23,190,452...23,225,102

G

TNFRSF10A antisense RNA 1

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of TNFRSF10A-AS1 mRNA] which results in increased expression of TNFRSF10A mRNA; [Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of TNFRSF10A-AS1 mRNA

Ensembl chr 8:23,189,279...23,190,675

G

TNRC6B divergent transcript

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of TNRC6B-DT mRNA] which results in increased expression of FAM83F mRNA; [Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of TNRC6B-DT mRNA

NCBI chr22:40,043,130...40,044,530
Ensembl chr22:40,043,068...40,044,565

G

tetratricopeptide repeat domain 23 like

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of TTC23L-AS1 mRNA] which results in increased expression of TTC23L mRNA

NCBI chr 5:34,839,164...34,925,682
Ensembl chr 5:34,838,833...34,900,511

G

TTC23L antisense RNA 1

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of TTC23L-AS1 mRNA] which results in increased expression of TTC23L mRNA; [Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of TTC23L-AS1 mRNA

NCBI chr 5:34,837,547...34,839,332
Ensembl chr 5:34,837,549...34,839,278

G

uroplakin 1A

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of UPK1A-AS1 mRNA] which results in increased expression of UPK1A mRNA

NCBI chr19:35,666,517...35,678,481
Ensembl chr19:35,666,517...35,678,481

G

UPK1A antisense RNA 1

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of UPK1A-AS1 mRNA] which results in increased expression of UPK1A mRNA; [Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of UPK1A-AS1 mRNA

NCBI chr19:35,667,948...35,673,291
Ensembl chr19:35,667,948...35,673,304

G

xanthine dehydrogenase

multiple interactions
increases abundance

[[Oxygen deficiency results in increased abundance of Hypoxanthine] affects the reaction [XDH protein affects the metabolism of Hypoxanthine]] which affects the abundance of Hydroxyl Radical
XDH protein results in increased abundance of Hydroxyl Radical

NCBI chr 2:31,334,321...31,414,742
Ensembl chr 2:31,334,321...31,414,742

G

zinc finger protein 114

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of ZNF114-AS1 mRNA] which results in increased expression of ZNF114 mRNA

NCBI chr19:48,270,081...48,287,608
Ensembl chr19:48,270,081...48,287,608

G

ZNF114 antisense RNA 1

multiple interactions

[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of ZNF114-AS1 mRNA] which results in increased expression of ZNF114 mRNA; [Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of ZNF114-AS1 mRNA

NCBI chr19:48,262,900...48,271,832
Ensembl chr19:48,262,900...48,271,283

lisinopril dihydrate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

angiotensin I converting enzyme

decreases activity

Lisinopril analog results in decreased activity of ACE protein

NCBI chr17:63,477,061...63,498,373
Ensembl chr17:63,477,061...63,498,380

G

angiotensin converting enzyme 2

increases expression
multiple interactions
increases activity

Lisinopril results in increased expression of ACE2 mRNA
ACE2 protein affects the reaction [[[Lisinopril co-treated with Thiorphan co-treated with N-benzyloxycarbonylprolylprolinal] affects the metabolism of AGT protein] which results in decreased abundance of angiotensin I (1-7)]
Lisinopril results in increased activity of ACE2 protein

PMID:15897343 PMID:16221218 PMID:27649628

NCBI chr X:15,518,197...15,607,211
Ensembl chr X:15,494,566...15,607,236

G

acetylcholinesterase (Yt blood group)

multiple interactions

2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [Lisinopril inhibits the reaction [Streptozocin results in increased activity of ACHE protein]]; Lisinopril inhibits the reaction [Streptozocin results in increased activity of ACHE protein]
Lisinopril inhibits the reaction [Sodium Fluoride results in decreased activity of ACHE protein]

PMID:23060470 PMID:31710167

NCBI chr 7:100,889,994...100,896,994
Ensembl chr 7:100,889,994...100,896,974

G

angiotensinogen

decreases expression
multiple interactions
affects metabolic processing
decreases secretion
increases secretion
affects response to substance
increases expression

Lisinopril results in decreased expression of AGT protein
[[Lisinopril co-treated with chymostatin] affects the metabolism of AGT protein] which results in decreased abundance of Angiotensin II; [[Lisinopril co-treated with Thiorphan co-treated with N-benzyloxycarbonylprolylprolinal] affects the metabolism of AGT protein] which results in decreased abundance of angiotensin I (1-7); [[Lisinopril co-treated with Thiorphan] affects the metabolism of AGT protein] which results in decreased abundance of angiotensin I (1-7); [Lisinopril affects the metabolism of AGT protein] which results in decreased abundance of Angiotensin II; [Lisinopril co-treated with chymostatin] affects the metabolism of AGT protein; [Lisinopril co-treated with Thiorphan co-treated with N-benzyloxycarbonylprolylprolinal] affects the metabolism of AGT protein; [Lisinopril co-treated with Thiorphan] affects the metabolism of AGT protein
[[Lisinopril co-treated with Thiorphan co-treated with N-benzyloxycarbonylprolylprolinal] affects the metabolism of AGT protein] which results in decreased abundance of angiotensin I (1-7); [[Lisinopril co-treated with Thiorphan] affects the metabolism of AGT protein] which results in decreased abundance of angiotensin I (1-7); [Lisinopril affects the metabolism of AGT protein] which results in decreased abundance of Angiotensin II; [Lisinopril affects the metabolism of AGT protein] which results in increased abundance of angiotensin I (1-7); [Lisinopril co-treated with Thiorphan co-treated with N-benzyloxycarbonylprolylprolinal] affects the metabolism of AGT protein; [Lisinopril co-treated with Thiorphan] affects the metabolism of AGT protein; ACE2 protein affects the reaction [[[Lisinopril co-treated with Thiorphan co-treated with N-benzyloxycarbonylprolylprolinal] affects the metabolism of AGT protein] which results in decreased abundance of angiotensin I (1-7)]; Thiorphan inhibits the reaction [[Lisinopril affects the metabolism of AGT protein] which results in increased abundance of angiotensin I (1-7)]
Lisinopril results in decreased secretion of AGT protein
Lisinopril results in increased secretion of AGT protein alternative form
[Lisinopril co-treated with Losartan] results in increased expression of AGT mRNA
AGT gene alternative form affects the susceptibility to Lisinopril
Lisinopril results in increased expression of AGT mRNA

PMID:8393685 PMID:8915971 PMID:15897343 PMID:16221218 PMID:16685205 More...

NCBI chr 1:230,702,523...230,745,583
Ensembl chr 1:230,690,776...230,745,576

G

BCL2 apoptosis regulator

decreases expression

Lisinopril results in decreased expression of BCL2

NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128

G

CD2 associated protein

multiple interactions

Lisinopril inhibits the reaction [Doxorubicin results in increased expression of CD2AP protein]

NCBI chr 6:47,477,789...47,627,263
Ensembl chr 6:47,477,789...47,627,263

G

endothelin 1

decreases secretion

Lisinopril results in decreased secretion of EDN1 protein

NCBI chr 6:12,230,516...12,297,194
Ensembl chr 6:12,290,361...12,297,194

G

growth hormone 1

multiple interactions

[Lisinopril co-treated with GH1 protein] inhibits the reaction [Doxorubicin results in decreased expression of TIMP1 protein]; [Lisinopril co-treated with GH1 protein] inhibits the reaction [Doxorubicin results in increased expression of MMP2 protein]; [Lisinopril co-treated with GH1 protein] inhibits the reaction [Doxorubicin results in increased expression of NOS2 mRNA]

NCBI chr17:63,917,203...63,918,839
Ensembl chr17:63,917,200...63,918,839

G

hepatitis A virus cellular receptor 1

multiple interactions

Lisinopril inhibits the reaction [Doxorubicin results in increased expression of HAVCR1 mRNA]; Lisinopril inhibits the reaction [Doxorubicin results in increased expression of HAVCR1 protein]

NCBI chr 5:157,029,413...157,069,407
Ensembl chr 5:157,026,742...157,069,396

G

major histocompatibility complex, class I, G

affects expression

Lisinopril affects the expression of HLA-G mRNA

NCBI chr 6:29,826,474...29,831,021
Ensembl chr 6:29,826,967...29,831,125

G

heparanase

multiple interactions

[Spironolactone co-treated with Lisinopril] inhibits the reaction [Doxorubicin results in increased expression of HPSE protein]; Lisinopril inhibits the reaction [Doxorubicin results in increased expression of HPSE protein]

NCBI chr 4:83,292,461...83,335,153
Ensembl chr 4:83,292,461...83,335,153

G

insulin like growth factor binding protein 1

increases expression

Lisinopril results in increased expression of IGFBP1 protein

NCBI chr 7:45,888,488...45,893,660
Ensembl chr 7:45,888,360...45,893,660

G

matrix metallopeptidase 2

multiple interactions

[Lisinopril co-treated with GH1 protein] inhibits the reaction [Doxorubicin results in increased expression of MMP2 protein]; Lisinopril inhibits the reaction [Doxorubicin results in increased expression of MMP2 protein]

NCBI chr16:55,478,830...55,506,691
Ensembl chr16:55,389,700...55,506,691

G

myeloperoxidase

multiple interactions

2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [Lisinopril inhibits the reaction [Streptozocin results in increased activity of MPO protein]]; Lisinopril inhibits the reaction [Streptozocin results in increased activity of MPO protein]

NCBI chr17:58,269,855...58,280,935
Ensembl chr17:58,269,855...58,280,935

G

nitric oxide synthase 2

multiple interactions

[Lisinopril co-treated with GH1 protein] inhibits the reaction [Doxorubicin results in increased expression of NOS2 mRNA]; Lisinopril inhibits the reaction [Doxorubicin results in increased expression of NOS2 mRNA]

NCBI chr17:27,756,766...27,800,529
Ensembl chr17:27,756,766...27,800,529

G

NPHS1 adhesion molecule, nephrin

multiple interactions

Lisinopril inhibits the reaction [Doxorubicin results in decreased phosphorylation of NPHS1 protein]; Lisinopril inhibits the reaction [Doxorubicin results in increased expression of NPHS1 protein]

PMID:16636307 PMID:19293598

NCBI chr19:35,862,915...35,869,357
Ensembl chr19:35,825,964...35,869,287

G

NPHS2 stomatin family member, podocin

multiple interactions

Lisinopril affects the reaction [Doxorubicin results in increased expression of NPHS2 mRNA]; Lisinopril affects the reaction [Doxorubicin results in increased expression of NPHS2 protein]

NCBI chr 1:179,550,539...179,575,948
Ensembl chr 1:179,550,539...179,575,952

G

natriuretic peptide A

decreases expression

Lisinopril results in decreased expression of NPPA protein

NCBI chr 1:11,845,709...11,847,783
Ensembl chr 1:11,845,709...11,848,345

G

renin

increases expression
multiple interactions

Lisinopril results in increased expression of REN protein
[Lisinopril co-treated with Losartan] results in increased expression of REN mRNA
Lisinopril results in increased expression of REN mRNA

PMID:2550029 PMID:8915971 PMID:16221218

NCBI chr 1:204,154,819...204,166,337
Ensembl chr 1:204,154,819...204,190,324

G

TIMP metallopeptidase inhibitor 1

multiple interactions

[Lisinopril co-treated with GH1 protein] inhibits the reaction [Doxorubicin results in decreased expression of TIMP1 protein]; Lisinopril inhibits the reaction [Doxorubicin results in decreased expression of TIMP1 protein]

NCBI chr X:47,582,436...47,586,789
Ensembl chr X:47,582,408...47,586,789

G

vascular endothelial growth factor A

multiple interactions

Lisinopril inhibits the reaction [Doxorubicin results in decreased expression of VEGFA protein]

NCBI chr 6:43,770,211...43,786,487
Ensembl chr 6:43,770,184...43,786,487

mosapride citrate dihydrate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

anoctamin 1

multiple interactions

mosapride inhibits the reaction [Loperamide results in decreased expression of ANO1 mRNA]; mosapride inhibits the reaction [Loperamide results in decreased expression of ANO1 protein]

NCBI chr11:69,965,997...70,189,530
Ensembl chr11:69,985,907...70,189,530

G

5-hydroxytryptamine receptor 4

multiple interactions

mosapride inhibits the reaction [Loperamide results in decreased expression of HTR4 mRNA]

NCBI chr 5:148,451,032...148,654,527
Ensembl chr 5:148,446,042...148,677,235

G

myosin light chain kinase

multiple interactions

mosapride inhibits the reaction [Loperamide results in decreased expression of MYLK mRNA]

NCBI chr 3:123,610,049...123,884,332
Ensembl chr 3:123,610,049...123,884,332

G

nitric oxide synthase 1

multiple interactions

mosapride inhibits the reaction [Loperamide results in decreased expression of NOS1 protein]

NCBI chr12:117,208,142...117,361,626
Ensembl chr12:117,208,142...117,452,170

G

ryanodine receptor 3

multiple interactions

mosapride inhibits the reaction [Loperamide results in decreased expression of RYR3 mRNA]

NCBI chr15:33,310,967...33,866,102
Ensembl chr15:33,310,962...33,866,121

G

solute carrier family 22 member 2

multiple interactions

mosapride inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]

NCBI chr 6:160,216,755...160,258,821
Ensembl chr 6:160,171,061...160,277,638

potassium citrate monohydrate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

neurofilament heavy chain

affects expression

Potassium Citrate affects the expression of NEFH mRNA

NCBI chr22:29,480,218...29,491,390
Ensembl chr22:29,480,218...29,491,390

royal jelly

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

BCL2 associated X, apoptosis regulator

multiple interactions

royal jelly inhibits the reaction [Fluorides results in decreased expression of BAX protein]

NCBI chr19:48,954,875...48,961,798
Ensembl chr19:48,954,815...48,961,798

G

BCL2 apoptosis regulator

multiple interactions

royal jelly inhibits the reaction [Nicotine results in decreased expression of BCL2 mRNA]
royal jelly inhibits the reaction [Fluorides results in increased expression of BCL2 protein]

PMID:30896085 PMID:34227456

NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128

G

brain derived neurotrophic factor

multiple interactions

royal jelly inhibits the reaction [Fluorides results in decreased expression of BDNF protein]

NCBI chr11:27,654,893...27,722,030
Ensembl chr11:27,654,893...27,722,058

G

caspase 3

multiple interactions

royal jelly inhibits the reaction [Nicotine results in increased expression of CASP3 mRNA]
royal jelly inhibits the reaction [Fluorides results in decreased expression of CASP3 protein]

PMID:30896085 PMID:34227456

NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062

G

caspase 6

multiple interactions

royal jelly inhibits the reaction [Fluorides results in decreased expression of CASP6 protein]

NCBI chr 4:109,664,388...109,709,767
Ensembl chr 4:109,688,622...109,703,583

G

caspase 9

multiple interactions

royal jelly inhibits the reaction [Fluorides results in decreased expression of CASP9 protein]

NCBI chr 1:15,491,401...15,524,912
Ensembl chr 1:15,490,832...15,526,534

G

catalase

multiple interactions

royal jelly inhibits the reaction [Cisplatin results in decreased activity of CAT protein]; royal jelly inhibits the reaction [Fluorides results in decreased activity of CAT protein]
royal jelly inhibits the reaction [Nicotine results in decreased activity of CAT protein]

PMID:20369241 PMID:30896085 PMID:34227456

NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060

G

cyclin D1

multiple interactions

royal jelly inhibits the reaction [phenylhydrazine affects the expression of CCND1 mRNA]

NCBI chr11:69,641,156...69,654,474
Ensembl chr11:69,641,156...69,654,474

G

E2F transcription factor 1

multiple interactions

royal jelly inhibits the reaction [Paclitaxel results in increased expression of E2F1 mRNA]

NCBI chr20:33,675,477...33,686,385
Ensembl chr20:33,675,477...33,686,385

G

estrogen receptor 1

multiple interactions
affects binding
increases activity

Estradiol inhibits the reaction [royal jelly binds to ESR1 protein]; royal jelly binds to and results in increased activity of ESR1 protein; royal jelly inhibits the reaction [Estradiol binds to ESR1 protein]
royal jelly results in increased activity of ESR1 protein

PMID:15946813 PMID:17287592

NCBI chr 6:151,656,672...152,129,619
Ensembl chr 6:151,656,691...152,129,619

G

estrogen receptor 2

multiple interactions
affects binding

Estradiol inhibits the reaction [royal jelly binds to ESR2 protein]; royal jelly binds to and results in increased activity of ESR2 protein; royal jelly inhibits the reaction [Estradiol binds to ESR2 protein]

PMID:15946813 PMID:17287592

NCBI chr14:64,226,707...64,338,613
Ensembl chr14:64,084,232...64,338,112

G

glycogen synthase kinase 3 beta

multiple interactions

royal jelly inhibits the reaction [Fluorides results in increased expression of GSK3B protein]

NCBI chr 3:119,821,321...120,094,447
Ensembl chr 3:119,821,321...120,094,994

G

INS-IGF2 readthrough

multiple interactions

royal jelly inhibits the reaction [Fructose results in increased expression of INS1 protein]

NCBI chr11:2,129,117...2,161,209
Ensembl chr11:2,132,538...2,161,209

G

MYC proto-oncogene, bHLH transcription factor

multiple interactions
decreases expression

royal jelly inhibits the reaction [phenylhydrazine results in decreased expression of MYC mRNA]
royal jelly results in decreased expression of MYC mRNA
royal jelly inhibits the reaction [Paclitaxel results in decreased expression of MYC mRNA]

PMID:27496854 PMID:35099105

NCBI chr 8:127,735,434...127,742,951
Ensembl chr 8:127,735,434...127,742,951

G

NFE2 like bZIP transcription factor 2

multiple interactions

royal jelly inhibits the reaction [Fluorides results in decreased expression of NFE2L2 protein]

NCBI chr 2:177,230,303...177,264,727
Ensembl chr 2:177,218,667...177,392,756

G

proliferating cell nuclear antigen

multiple interactions

royal jelly inhibits the reaction [Nicotine results in decreased expression of PCNA protein]

NCBI chr20:5,114,953...5,126,622
Ensembl chr20:5,114,953...5,126,626

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

royal jelly inhibits the reaction [Fluorides results in increased expression of RELA protein]

NCBI chr11:65,653,601...65,663,857
Ensembl chr11:65,653,599...65,663,090

G

trefoil factor 1

increases expression

royal jelly results in increased expression of TFF1 mRNA

NCBI chr21:42,362,282...42,366,535
Ensembl chr21:42,362,282...42,366,535

G

tumor protein p53

multiple interactions

royal jelly inhibits the reaction [Nicotine results in increased expression of TRP53 mRNA]

NCBI chr17:7,668,421...7,687,490
Ensembl chr17:7,661,779...7,687,546

G

vascular endothelial growth factor A

increases expression

royal jelly results in increased expression of VEGFA mRNA

PMID:15946813 PMID:17287592

NCBI chr 6:43,770,211...43,786,487
Ensembl chr 6:43,770,184...43,786,487

sodium acetate trihydrate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acyl-CoA oxidase 1

increases expression

Sodium Acetate results in increased expression of ACOX1 mRNA

NCBI chr17:75,941,507...75,979,166
Ensembl chr17:75,941,507...75,979,177

G

acyl-CoA synthetase short chain family member 1

increases expression

Sodium Acetate results in increased expression of ACSS1 mRNA

NCBI chr20:25,006,237...25,058,139
Ensembl chr20:25,006,230...25,058,980

G

acyl-CoA synthetase short chain family member 2

increases expression

Sodium Acetate results in increased expression of ACSS2 mRNA

NCBI chr20:34,874,989...34,927,959
Ensembl chr20:34,872,146...34,927,962

G

adenosine deaminase

multiple interactions

Sodium Acetate inhibits the reaction [Nicotine results in increased activity of ADA protein]

NCBI chr20:44,619,522...44,651,699
Ensembl chr20:44,584,896...44,652,252

G

apolipoprotein B

multiple interactions

[Sodium Acetate co-treated with acetic anhydride] results in increased acetylation of APOB protein

NCBI chr 2:21,001,429...21,044,073
Ensembl chr 2:21,001,429...21,044,073

G

caspase 3

multiple interactions

Sodium Acetate inhibits the reaction [Cisplatin results in increased cleavage of CASP3 protein]

NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062

G

caspase 7

multiple interactions

Sodium Acetate inhibits the reaction [Cisplatin results in increased cleavage of CASP7 protein]

NCBI chr10:113,679,194...113,730,909
Ensembl chr10:113,679,162...113,730,907

G

catalase

multiple interactions

Sodium Acetate inhibits the reaction [Cisplatin results in decreased expression of CAT protein]

NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060

G

cytochrome P450 family 1 subfamily A member 1

multiple interactions

Sodium Acetate promotes the reaction [biochanin A results in increased expression of CYP1A1 mRNA]; Sodium Acetate promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]

NCBI chr15:74,719,542...74,725,528
Ensembl chr15:74,719,542...74,725,536

G

cytochrome P450 family 1 subfamily B member 1

multiple interactions

Sodium Acetate promotes the reaction [biochanin A results in increased expression of CYP1B1 mRNA]; Sodium Acetate promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1B1 mRNA]

NCBI chr 2:38,067,509...38,076,151
Ensembl chr 2:38,066,973...38,109,902

G

gamma-glutamyltransferase 1

multiple interactions

Sodium Acetate inhibits the reaction [Nicotine results in increased activity of GGT1 protein]

NCBI chr22:24,583,750...24,628,996
Ensembl chr22:24,594,811...24,629,005

G

interferon gamma

multiple interactions

[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of IFNG mRNA]

NCBI chr12:68,154,768...68,159,740
Ensembl chr12:68,154,768...68,159,740

G

inhibitor of nuclear factor kappa B kinase subunit beta

multiple interactions

[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of IKBKB mRNA]; [Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of IKBKB protein]

NCBI chr 8:42,271,302...42,332,460
Ensembl chr 8:42,271,302...42,332,460

G

interleukin 2

multiple interactions

Sodium Acetate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased activity of IL2 protein]

NCBI chr 4:122,451,470...122,456,725
Ensembl chr 4:122,451,470...122,456,725

G

interleukin 6

multiple interactions

[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of IL6 mRNA]

NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002

G

INS-IGF2 readthrough

multiple interactions

Sodium Acetate inhibits the reaction [Nicotine results in increased expression of INS1 protein]

NCBI chr11:2,129,117...2,161,209
Ensembl chr11:2,132,538...2,161,209

G

karyopherin subunit beta 1

multiple interactions

Sodium Acetate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] promotes the reaction [NFATC2 protein binds to KPNB1 protein]]

NCBI chr17:47,649,919...47,685,505
Ensembl chr17:47,649,476...47,685,505

G

MYD88 innate immune signal transduction adaptor

multiple interactions

[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of MYD88 mRNA]

NCBI chr 3:38,138,661...38,143,022
Ensembl chr 3:38,138,552...38,143,024

G

N-acetyltransferase 2

increases expression

Sodium Acetate results in increased expression of NAT2 mRNA

NCBI chr 8:18,386,301...18,401,218
Ensembl chr 8:18,391,282...18,401,218

G

nuclear factor of activated T cells 2

multiple interactions

Sodium Acetate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] affects the localization of NFATC2 protein]; Sodium Acetate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] promotes the reaction [NFATC2 protein binds to KPNB1 protein]]; Sodium Acetate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased activity of NFATC2 protein]

NCBI chr20:51,386,963...51,562,839
Ensembl chr20:51,386,957...51,562,831

G

NFKB inhibitor alpha

multiple interactions

[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in decreased expression of NFKBIA protein]

NCBI chr14:35,401,513...35,404,749
Ensembl chr14:35,401,079...35,404,749

G

phosphoenolpyruvate carboxykinase 1

increases expression

Sodium Acetate results in increased expression of PCK1 mRNA

NCBI chr20:57,561,110...57,568,121
Ensembl chr20:57,561,080...57,568,121

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of and results in increased phosphorylation of RELA protein]; [Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of RELA mRNA]

NCBI chr11:65,653,601...65,663,857
Ensembl chr11:65,653,599...65,663,090

G

superoxide dismutase 2

multiple interactions

Sodium Acetate inhibits the reaction [Cisplatin results in decreased expression of SOD2 protein]

NCBI chr 6:159,669,069...159,762,281
Ensembl chr 6:159,669,069...159,762,529

G

transforming growth factor beta 1

multiple interactions

[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of TGFB1 mRNA]

NCBI chr19:41,330,323...41,353,922
Ensembl chr19:41,301,587...41,353,922

G

toll like receptor 2

multiple interactions

[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of TLR2 mRNA]; [Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of TLR2 protein]

NCBI chr 4:153,684,280...153,710,637
Ensembl chr 4:153,684,050...153,706,260

G

toll like receptor 4

multiple interactions

[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of TLR4 mRNA]; [Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of TLR4 protein]

NCBI chr 9:117,704,403...117,724,735
Ensembl chr 9:117,704,175...117,724,735

G

tumor necrosis factor

multiple interactions

[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of TNF mRNA]

NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336

G

UDP glucuronosyltransferase family 1 member A1

multiple interactions

Sodium Acetate promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of UGT1A1 mRNA]

NCBI chr 2:233,760,270...233,773,300
Ensembl chr 2:233,760,270...233,773,300

G

xanthine dehydrogenase

multiple interactions

Sodium Acetate inhibits the reaction [Nicotine results in increased activity of XDH protein]

NCBI chr 2:31,334,321...31,414,742
Ensembl chr 2:31,334,321...31,414,742

sodium thiosulfate pentahydrate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

caspase 3

multiple interactions

sodium thiosulfate inhibits the reaction [Isoproterenol results in increased activity of CASP3 protein]

NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062

G

caspase 9

multiple interactions

sodium thiosulfate inhibits the reaction [Isoproterenol results in increased activity of CASP9 protein]

NCBI chr 1:15,491,401...15,524,912
Ensembl chr 1:15,490,832...15,526,534

G

myeloperoxidase

multiple interactions

sodium thiosulfate inhibits the reaction [Isoproterenol results in increased activity of MPO protein]

NCBI chr17:58,269,855...58,280,935
Ensembl chr17:58,269,855...58,280,935

tacrolimus hydrate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

alpha-2-macroglobulin

increases expression

Tacrolimus results in increased expression of A2M mRNA

NCBI chr12:9,067,708...9,116,229
Ensembl chr12:9,067,664...9,116,229

G

ATP binding cassette subfamily A member 1

multiple interactions
increases expression

[Sirolimus co-treated with Tacrolimus] results in increased expression of ABCA1 protein
Tacrolimus results in increased expression of ABCA1 mRNA

PMID:17016853 PMID:21865292

NCBI chr 9:104,781,006...104,928,155
Ensembl chr 9:104,781,006...104,928,155

G

ATP binding cassette subfamily B member 1

increases response to substance
decreases activity
affects export
multiple interactions
increases export
affects response to substance

ABCB1 gene SNP results in increased susceptibility to Tacrolimus
Tacrolimus results in decreased activity of ABCB1 protein
ABCB1 protein affects the export of Tacrolimus
[Tacrolimus binds to ABCB1 protein] inhibits the reaction [azidoprazosin binds to ABCB1 protein]; [Tacrolimus results in decreased activity of ABCB1 protein] which results in decreased export of Dexamethasone; Verapamil affects the reaction [ABCB1 protein results in increased export of Tacrolimus]
ABCB1 protein affects the susceptibility to Tacrolimus

PMID:1381629 PMID:11920757 PMID:12352921 PMID:15919446 PMID:15964336 More...

NCBI chr 7:87,503,017...87,713,295
Ensembl chr 7:87,503,017...87,713,323

G

ATP binding cassette subfamily B member 11

decreases activity

Tacrolimus results in decreased activity of ABCB11 protein

NCBI chr 2:168,915,390...169,031,324
Ensembl chr 2:168,915,498...169,031,324

G

acetyl-CoA acyltransferase 1

decreases expression

Tacrolimus results in decreased expression of ACAA1B mRNA

NCBI chr 3:38,122,715...38,137,127
Ensembl chr 3:38,103,129...38,137,242

G

acyl-CoA dehydrogenase long chain

decreases expression

Tacrolimus results in decreased expression of ACADL mRNA

NCBI chr 2:210,187,923...210,225,447
Ensembl chr 2:210,187,126...210,225,447

G

angiotensin converting enzyme 2

decreases expression

Tacrolimus results in decreased expression of ACE2 mRNA

NCBI chr X:15,518,197...15,607,211
Ensembl chr X:15,494,566...15,607,236

G

acid phosphatase 5, tartrate resistant

multiple interactions

Tacrolimus inhibits the reaction [TNFSF11 protein results in increased expression of ACP5 protein]

NCBI chr19:11,574,660...11,578,975
Ensembl chr19:11,574,653...11,579,993

G

actin alpha 2, smooth muscle

increases expression

Tacrolimus results in increased expression of ACTA2 protein

NCBI chr10:88,935,074...88,991,337
Ensembl chr10:88,934,822...88,991,339

G

activin A receptor type 1B

multiple interactions

[Tacrolimus inhibits the reaction [FKBP1A protein binds to ACVR1B protein]] which results in decreased ubiquitination of ACVR1B protein; Tacrolimus inhibits the reaction [FKBP1A protein binds to and results in decreased activity of ACVR1B protein]; Tacrolimus inhibits the reaction [FKBP1A protein promotes the reaction [SMURF1 protein binds to SMAD7 protein binds to ACVR1B protein]]

NCBI chr12:51,951,699...51,997,078
Ensembl chr12:51,951,699...51,997,078

G

ADAM metallopeptidase with thrombospondin type 1 motif 1

increases expression

Tacrolimus results in increased expression of ADAMTS1 mRNA

NCBI chr21:26,835,755...26,845,409
Ensembl chr21:26,835,755...26,845,409

G

ADAM metallopeptidase with thrombospondin type 1 motif 2

increases expression

Tacrolimus results in increased expression of ADAMTS2 mRNA

NCBI chr 5:179,110,853...179,345,461
Ensembl chr 5:179,110,853...179,345,461

G

adenylate cyclase 9

multiple interactions

Tacrolimus inhibits the reaction [Calcium inhibits the reaction [Miconazole results in increased activity of ADCY9 protein]]

NCBI chr16:3,953,387...4,116,442
Ensembl chr16:3,953,387...4,116,442

G

adrenoceptor alpha 1D

increases expression

Tacrolimus results in increased expression of ADRA1D mRNA

NCBI chr20:4,220,630...4,249,287
Ensembl chr20:4,220,630...4,249,287

G

allograft inflammatory factor 1

increases expression

Tacrolimus results in increased expression of AIF1 mRNA

NCBI chr 6:31,615,234...31,617,015
Ensembl chr 6:31,615,217...31,617,021

G

aldehyde dehydrogenase 1 family member A1

decreases expression

Tacrolimus results in decreased expression of ALDH1A1 mRNA

NCBI chr 9:72,900,671...72,953,053
Ensembl chr 9:72,900,671...73,080,442

G

aldehyde dehydrogenase 2 family member

decreases expression

Tacrolimus results in decreased expression of ALDH2 mRNA

NCBI chr12:111,766,933...111,817,532
Ensembl chr12:111,766,887...111,817,532

G

aldehyde dehydrogenase 9 family member A1

decreases expression

Tacrolimus results in decreased expression of ALDH9A1 mRNA

NCBI chr 1:165,662,216...165,698,562
Ensembl chr 1:165,662,216...165,698,562

G

ALG3 alpha-1,3- mannosyltransferase

decreases expression

Tacrolimus results in decreased expression of ALG3 mRNA

NCBI chr 3:184,242,301...184,249,525
Ensembl chr 3:184,242,301...184,249,548

G

angiopoietin like 6

increases expression

Tacrolimus results in increased expression of ANGPTL6 mRNA

NCBI chr19:10,092,338...10,106,190
Ensembl chr19:10,092,338...10,102,678

G

ankyrin repeat domain 1

increases expression

Tacrolimus results in increased expression of ANKRD1 mRNA

NCBI chr10:90,912,096...90,921,087
Ensembl chr10:90,912,096...90,921,087

G

ankyrin repeat domain 34A

decreases expression

Tacrolimus results in decreased expression of ANKRD34A mRNA

NCBI chr 1:145,959,441...145,964,575
Ensembl chr 1:145,959,441...145,964,575

G

alanyl aminopeptidase, membrane

increases secretion

Tacrolimus results in increased secretion of ANPEP protein

NCBI chr15:89,784,895...89,814,852
Ensembl chr15:89,784,895...89,815,401

G

annexin A1

increases expression

Tacrolimus results in increased expression of ANXA1

NCBI chr 9:73,151,865...73,170,393
Ensembl chr 9:73,151,865...73,170,393

G

amine oxidase copper containing 1

increases expression

Tacrolimus results in increased expression of AOC1 mRNA

NCBI chr 7:150,852,120...150,861,504
Ensembl chr 7:150,824,627...150,861,504

G

amphiregulin

increases expression

Tacrolimus results in increased expression of AREG mRNA

NCBI chr 4:74,445,136...74,455,005
Ensembl chr 4:74,445,136...74,455,005

G

ADP ribosylation factor related protein 1

increases expression

Tacrolimus results in increased expression of ARFRP1 mRNA

NCBI chr20:63,698,647...63,707,976
Ensembl chr20:63,698,642...63,708,025

G

Rho GTPase activating protein 45

increases expression

Tacrolimus results in increased expression of ARHGAP45 mRNA

NCBI chr19:1,065,959...1,086,628
Ensembl chr19:1,065,923...1,086,628

G

Rho guanine nucleotide exchange factor 11

increases expression

Tacrolimus results in increased expression of ARHGEF11 mRNA

NCBI chr 1:156,934,840...157,046,903
Ensembl chr 1:156,934,840...157,046,903

G

actin related protein 2/3 complex subunit 5

increases expression

Tacrolimus results in increased expression of ARPC5 mRNA

NCBI chr 1:183,620,846...183,635,783
Ensembl chr 1:183,620,846...183,635,783

G

ARV1 homolog, fatty acid homeostasis modulator

increases expression

Tacrolimus results in increased expression of ARV1 mRNA

NCBI chr 1:230,979,094...231,000,733
Ensembl chr 1:230,978,981...231,000,733

G

ASXL transcriptional regulator 3

decreases expression

Tacrolimus results in decreased expression of ASXL3 mRNA

NCBI chr18:33,578,219...33,751,195
Ensembl chr18:33,578,219...33,751,195

G

activating transcription factor 3

increases expression

Tacrolimus results in increased expression of ATF3 mRNA

NCBI chr 1:212,565,407...212,620,777
Ensembl chr 1:212,565,334...212,620,777

G

activating transcription factor 4

increases expression

Tacrolimus results in increased expression of ATF4 mRNA

NCBI chr22:39,520,559...39,522,686
Ensembl chr22:39,519,695...39,522,683

G

activating transcription factor 6

increases expression

Tacrolimus results in increased expression of ATF6 mRNA

NCBI chr 1:161,766,320...161,964,070
Ensembl chr 1:161,766,298...161,977,574

G

ATPase Na+/K+ transporting subunit beta 1

decreases expression

Tacrolimus results in decreased expression of ATP1B1 mRNA

NCBI chr 1:169,106,690...169,132,719
Ensembl chr 1:169,105,697...169,310,992

G

ATPase Na+/K+ transporting subunit beta 3

decreases expression

Tacrolimus results in decreased expression of ATP1B3 mRNA

NCBI chr 3:141,876,643...141,926,549
Ensembl chr 3:141,876,124...141,926,549

G

ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2

increases expression

Tacrolimus results in increased expression of ATP2A2 mRNA

NCBI chr12:110,280,616...110,351,093
Ensembl chr12:110,280,756...110,351,093

G

beta-2-microglobulin

increases expression

Tacrolimus results in increased expression of B2M mRNA

NCBI chr15:44,711,517...44,718,145
Ensembl chr15:44,711,358...44,718,851

G

BCL2 associated agonist of cell death

multiple interactions

Tacrolimus inhibits the reaction [Ammonium Chloride results in decreased phosphorylation of BAD protein]
Tacrolimus inhibits the reaction [Rotenone results in decreased phosphorylation of BAD protein]

PMID:15036616 PMID:15280438

NCBI chr11:64,269,828...64,284,704
Ensembl chr11:64,269,830...64,284,704

G

basic leucine zipper ATF-like transcription factor 3

increases expression

Tacrolimus results in increased expression of BATF3 mRNA

NCBI chr 1:212,686,417...212,699,840
Ensembl chr 1:212,686,417...212,699,840

G

BCL2 associated X, apoptosis regulator

multiple interactions
increases expression

Tacrolimus inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of BAX protein]
Tacrolimus results in increased expression of BAX protein
[Tacrolimus co-treated with 3-nitropropionic acid] affects the localization of BAX protein

PMID:10205001 PMID:15571979 PMID:27606422 PMID:35033536

NCBI chr19:48,954,875...48,961,798
Ensembl chr19:48,954,815...48,961,798

G

BCL2 apoptosis regulator

multiple interactions
decreases expression
increases expression

Tacrolimus inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in decreased expression of BCL2 protein]
Tacrolimus results in decreased expression of BCL2 protein
[Tacrolimus co-treated with 3-nitropropionic acid] affects the localization of BCL2 protein
Tacrolimus results in increased expression of BCL2 protein

PMID:10205001 PMID:15571979 PMID:27606422

NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128

G

BCL2 like 1

multiple interactions

Tacrolimus inhibits the reaction [Superantigens results in increased expression of BCL2L1 protein]

NCBI chr20:31,664,452...31,723,963
Ensembl chr20:31,664,452...31,723,989